This may include, but is not limite d to, redaction of the following: 

•Title: A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two-Part 
Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole from 
Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH 
Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg 
Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant 
Study ID: [REMOVED]
Protocol Approve Date: 06 June 2017
Certain information  within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information 
or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
TITLE PAGE
PROTOCOL AMENDMENT
A Phase 1, Randomized, Open -Label, Single -Center, Single -Dose, Two- Period Two- Part 
Crossover Study in Healthy Subjects to Compare the Bioavailability of 
Dexlansoprazole from Dexlansoprazole Delayed -Release Capsules 30 mg and 60 mg 
Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole 
Delayed -Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical 
Company Limited Osaka Pla nt 
Phase 1 Bioequivalence Study of Dexlansoprazole Capsules from Two Manufacturing Plants
Sponsor: Takeda Development Center Americas, Inc.
One Takeda Parkway , Deerfield, IL 60015
Study Number: TAK -390MR -1001
IND Number: 069927 EudraCT Number: Not Appl icable
Compound: Dexlansoprazole Delayed -Release Capsules
Date: 06 June 2017 Amendment Number: 02
Amendment History: 
Date Amendment Number Amendment Type Region
28 October 2016 Initial Protocol Not applicable USA
30 March 2017 01 Nonsubstantial USA
06 June 2017 02 Nonsubstantial USA
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
Dexlansoprazole Delayed-Release Capsules
Study No. TAK-390MR-1001 Page 2 of 82Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL1.0 ADMINISTRATIVE INFORMATION
1.1 Contacts
A separate contact information list will be provided to each site.Takeda-sponsored investigators per individual country requirements will be provided with 
emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section  3.1and relevant guidelines should 
be provided to the site.
Contact Type / Role Contact
Serious adverse event and pregnancy reporting
Primary Medical Monitor (primary medical 
monitor for the study providing medical advice on protocol and compound)
Takeda Medical Monitor (medical advice on 
protocol and compound if primary medical monitor not available)
Responsible Medical Officer (carries overall 
responsibility for the conduct of the study)Personal Protected Data
Dexlansoprazole Delayed-Release Capsules
Study No. TAK-390MR-1001 Page 3 of 82Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL1.2 Approval
REPRESENTATIVES OF TAKEDAThis study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
Electronic Signatures may be found on th e last page of this document.
Personal Protected Data
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 4of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALINVESTIGATOR AGREEMENT
I confirm that I have read and th at I understand this protocol, the package insert, and any other 
product informat ion provi ded by  the sponsor. I agree to conduct this study  in accordance with the 
requi rements of this protocol and also to protect the rights, safet y, privacy, and well -being of study 
subjects in accordance with the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Appendix B-Responsibilit ies of the Investigator.
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signature of Investigator Date
Invest igator Name (print or type)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 5of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL1.3 Protocol Amendment 02 Summary of Changes
Rationale for Amendment 02
This document describes the changes in reference to the protocol incorporating Amendment 02. 
The primary  reason for thi s amendment is to allow the replacement of subjects who are 
discontinued or withdrawn.
For specific descript ions of the changes listed belo w and where these changes are located, see 
Appendix F.
Changes in Amendment 02
1.Allow the replacement of subjects who are discontinued or withdrawn.
2.Correct the dose shown in Part 2 of the crossover study  design schemat ic.
3.Remove all reference to the subject’s legally acceptable representative.
4.Update the definit ions of wo men of (and not of) childbearing potential.
5.Update the subject replacement information based on the allowance for replaced subjects.
6.Clarify  that an 8 -hour fast m ay not be possible at Early  terminat ion.
7.Correct the sequence numbers in Table 8.bfor Part 2 of the study .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 6of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 02 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 11
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 15
3.1 Study -Related Responsibilit ies................................................................................. 15
3.2 Principal Invest igator ............................................................................................... 15
3.3 List of Abbreviat ions............................................................................................... 16
3.4 Corporate Identificat ion........................................................................................... 17
4.0 INTRODUCTION ......................................................................................................... 18
4.1 Background ............................................................................................................. 18
4.2 Rationale for the Proposed Study ............................................................................. 18
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 19
5.1 Object ives................................................................................................................ 19
5.1.1 Primary Object ive(s) ................................................................................... 19
5.1.2 Addit ional Objectives .................................................................................. 19
5.2 Endpoints ................................................................................................................. 19
5.2.1 Primary Endpo ints....................................................................................... 19
5.2.2 Addit ional Endpo ints.................................................................................. 19
5.2.3 Safety Endpo ints......................................................................................... 19
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 20
6.1 Study  Design ........................................................................................................... 20
6.2 Justification for Study  Desi gn, Dose, and Endpoints ................................................ 22
6.3 Prem ature Terminat ion or Suspension o f Study  or Invest igational Si te..................... 23
6.3.1 Criteria for Premature Terminat ion or Suspension of the Study ................... 23
6.3.2 Criteria for Premature Terminat ion or Suspension of Invest igational Si tes..23
6.3.3 Procedures for Premature Termination or Suspension of the Study  or the 
Parti cipation of  Invest igational Si te(s) ......................................................... 23
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 24
7.1 Inclusio n Cri teria..................................................................................................... 24
7.2 Exclusio n Cri teria.................................................................................................... 24
7.3 Excluded Medicat ions and Dietary  Products ............................................................ 26
7.4 Diet, Fl uid and Act ivity Control ............................................................................... 27
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 7of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL7.4.1 Confinement ............................................................................................... 27
7.4.2 Diet and Fluid ............................................................................................. 27
7.4.3 Activity Control .......................................................................................... 28
7.5 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 28
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 29
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ...................................................... 30
8.1 Study  Medicat ion..................................................................................................... 30
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling .............................. 30
8.1.2 Storage ........................................................................................................ 30
8.1.3 Dose and Regimen ...................................................................................... 30
8.1.4 Overdose ..................................................................................................... 31
8.2 Invest igational Drug Assignment and Dispensing Procedures .................................. 32
8.3 Randomization Code Creation and Storage .............................................................. 32
8.4 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 32
8.5 Reserve Study  Medicati on Samples for Retention .................................................... 34
9.0 STUDY PLAN .............................................................................................................. 35
9.1 Study  Procedures ..................................................................................................... 35
9.1.1 Inform ed Consent Procedure ....................................................................... 35
9.1.1.1 Pharmacogeno mic Informed Consent Procedure ..................................... 35
9.1.2 Dem ographics, Medi cal History , and Medicat ion History  Procedure ........... 35
9.1.3 Physical Examinat ion Procedure .................................................................35
9.1.4 Weight, Height and BMI ............................................................................. 36
9.1.5 Vital Sign Procedure ................................................................................... 36
9.1.6 Docum entati on of  Conco mitant Medi cations............................................... 37
9.1.7 Docum entati on of  Concurrent Medi cal Condit ions...................................... 37
9.1.8 Procedures for Clinical Laboratory  Samples ................................................ 37
9.1.9 Contraception and Pregnancy Avo idance Procedure .................................... 39
9.1.10 Pregnancy ................................................................................................... 40
9.1.11 ECG Procedure ........................................................................................... 40
9.1.12 Pharmacogeno mic Sample Co llection......................................................... 40
9.1.13 PK Sam ple Collect ion................................................................................. 41
9.1.13.1 Collect ion of Blood for PK Sampling ..................................................... 41
9.1.14 PK Parameters ............................................................................................. 42
9.1.15 Docum entati on of  Screen Failure ................................................................ 42
9.1.16 Docum entati on of  Rando mization ............................................................... 43
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 8of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.2 Moni toring Subject Treatment Compliance .............................................................. 43
9.3 Schedule of Observat ions and Procedures ................................................................ 43
9.3.1 Screening .................................................................................................... 43
9.3.2 Check -in (Day -1)....................................................................................... 44
9.3.3 Treatment Phase (Day  1)............................................................................. 44
9.3.4 Day 2 (Peri od 1) .......................................................................................... 45
9.3.5 Day 2 (Peri od 2)/Study  Exit........................................................................ 45
9.3.6 Early Terminat ion....................................................................................... 45
9.3.7 Follow-up ................................................................................................... 46
9.3.8 Unscheduled Visit ....................................................................................... 46
9.4 Biological Sample Retent ion and Destruction .......................................................... 46
9.5 Blood Vol ume ......................................................................................................... 47
10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................ 48
10.1 Definit ions............................................................................................................... 48
10.1.1 Pretr eatment Events .................................................................................... 48
10.1.2 AEs............................................................................................................. 48
10.1.3 Addit ional Po ints to Consider for PTEs and AEs ......................................... 48
10.1.4 SAEs ........................................................................................................... 50
10.1.5 Severit y of PTEs and AEs ........................................................................... 51
10.1.6 Causalit y of AEs......................................................................................... 51
10.1.7 Relationship to Study  Procedures ................................................................ 51
10.1.8 Start Date .................................................................................................... 52
10.1.9 Stop Date .................................................................................................... 52
10.1.10 Frequency ................................................................................................... 52
10.1.11 Action Concerning Study  Medicat ion.......................................................... 52
10.1.12 Outcom e..................................................................................................... 52
10.2 Procedures ............................................................................................................... 53
10.2.1 Collect ion and Reporti ng of AEs.................................................................53
10.2.1.1 PTEs and AEs Collection Period ............................................................ 53
10.2.1.2 PTEs and AEs Reporting ........................................................................ 53
10.2.2 Collect ion and Reporti ng of SAEs ............................................................... 54
10.2.3 Reporting of Abnormal LFTs ...................................................................... 54
10.3 Follow-up of  SAEs .................................................................................................. 54
10.3.1 Safety Reporting to Invest igators, IRBs and Regulatory  Authori ties............ 55
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 56
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 9of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 57
12.1 CRFs (El ectronic) .................................................................................................... 57
12.2 Record Retention ..................................................................................................... 57
13.0 STATISTICAL METHODS .......................................................................................... 59
13.1 Statistical and Analyt ical Plans ................................................................................ 59
13.1.1 Analysis Sets ............................................................................................... 59
13.1.2 Analysis of Demographics and Other Baseline Characterist ics.................... 59
13.1.3 PK Analysis ................................................................................................ 59
13.1.4 Safety Analysis ........................................................................................... 60
13.2 Interim Analysis and Criteria for Early Terminat ion................................................ 60
13.3 Determinat ion of Sample Size .................................................................................. 60
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 61
14.1 Study -Site Moni toring Visit s................................................................................... 61
14.2 Protocol  Deviat ions.................................................................................................. 61
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 62
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 63
15.1 IRB Approval .......................................................................................................... 63
15.2 Subje ct Inf ormation, Inform ed Consent, and Subject Authorizat ion......................... 64
15.3 Subject Confidentialit y............................................................................................ 65
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................65
15.4.1 Publicat ion and Disclosure .......................................................................... 65
15.4.2 Clinical Trial Registration ........................................................................... 66
15.4.3 Clinical Trial Result s Disclosure .................................................................66
15.5 Insurance and Co mpensation for Injury .................................................................... 66
16.0 REFERENCES .............................................................................................................. 67
LIST OF IN -TEXT TABLES
Table 6.a Part 1 Sequences ................................................................................................ 20
Table 6.b Part 2 Sequences ................................................................................................ 21
Table 7.a Prohibited Medications, Supplements, and Dietary  Products .............................. 27
Table 8.a Study  Medicat ion –Sponsor Supplied ................................................................ 30
Table 8.b Dose and Regimen ............................................................................................. 31
Table 9.a Clinical Laboratory  Tests ................................................................................... 38
Table 9.b Collect ion of Blood Sam ples for PK Analysis .................................................... 41
Table 9.c Approximate Blood Volume .............................................................................. 47
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 10of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALTable 10.a Takeda Medically Significant AE List ................................................................ 51
Table 14.a Windows for PK Sample Co llection................................................................... 61
LIST OF IN -TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 22
Figure 6.b Schemat ic of Crossover Design .......................................................................... 22
LIST OF APPENDICES
Append ix A Schedule of Study  Procedures ............................................................................ 68
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 70
Appendix C Elements of the Subject Informed Consent ......................................................... 72
Appendix D Invest igator Consent to Use of Personal Informat ion.......................................... 75
Appendix E Collect ion, Storage, and Ship ment of Bi oanaly tical Samples .............................. 76
Appendix F Detailed Descript ion of Amendments to Text ..................................................... 79
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 11of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL2.0 STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc.Compound:
Dexlansoprazole Delayed -Release Capsules
Title of Protocol: A Phase 1, Randomized, Open -Label, 
Single -Center, Single -Dose, Two -Period Two Part 
Crossover Study in Healthy Subjects to Compare the 
Bioavailability of Dexlansoprazole from Dexlansoprazole 
Delayed -Release Capsules 30 mg and 60 mg Manufactured 
by Takeda G mbH Plant Oranienburg Relative to 
Dexlansoprazole Delayed -Release Capsules 30 mg and 60 
mg Manufactured by Takeda Pharmaceutical Company 
Limited Osaka PlantIND No.: 
069927EudraCT No.:
Not applicable
Study Number: TAK -390MR -1001 Phase: 1
Study Design:
This is a phase 1, randomized, open -label, single -center, single -dose, 2 -part, 2-wa y crossover bioavailability (BA) 
study to compare the BA of 30 or 60 mg dexlansoprazole capsules manufactured at Takeda GmbH Plant Oranienburg 
(TOB) to the corresponding 30 or 60mg dexlansoprazole capsules manufactured at Takeda Pharmaceutical Company 
Ltd. (TPC) plant in Osaka, Japan. The study will be conducted in 2 parts. In Part 1, 52 healthy  subjects will receive 
dexlansoprazole 30 mg capsules manufactured by TOB and TPC in a crossover fashion. In Part 2, an additional 
52healthy  subjects will receive dexlansoprazole 60 mg capsules manufactured by TOB and TPC in a crossover 
fashion. Due to the difference between the Granules -L used in the 30 mg (Granules -LL) and 60 mg (Gr anules -LS) 
capsules, the relative BA of both dosage strengths will be assessed. If bioequivalence (BE) is not achieved with the 
first TOB formulation, the study may be repeated for one or both dose strengths in new subjects who will receive the 
same TOB fo rmulatio n or a different TOB formulation. The same study design will be used if additional formulation 
assessments are needed.
Subjects who satisfy the Screening evaluation and selection criteria may be enrolled in the study. For each part, 
eligible subjec ts will be randomized on Day 1 of Period 1 in a 1:1 ratio to 1 of 2 sequences, which defines the order in 
which they will receive dexlansoprazole regimens in Periods 1 and 2. The dosing between Periods will be separated by 
a minimum 5 -day washout interval. During Periods 1 and 2, blood samples will be collected over 24 hours postdose to 
measure dexlansoprazole plasma concentrations. The treatment sequences are outlined in the following tables for 
Part1 and for Part 2.
Part 1 Sequences
Sequences Number of Subjects Period 1 Period 2
1 26 A B
2 26 B A
Regimen A (test): A single dexlansoprazole 30 mg capsule manufactured at TOB administered orally on Day 1 
following a 10- hour fast.
Regimen B (reference): A single dexlansoprazole 30 mg capsule manufactured at TPC administered orally on Day 1 
following a 10- hour fast. 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 12of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALPart 2 Sequences
Sequences Number of Subjects Period 1 Period 2
3 26 C D
4 26 D C
Regimen C (test): A single dexlansoprazole 60 mg capsule manufactured at TOB administered orally on Day 1 
following a 10- hour fast.
Regimen D (reference): A single dexlansoprazole 60 mg capsule manufactured at TPC administered orally on Day 1 
following a 10- hour fast. 
In each perio d of each part, subjects will be confined from Check -in Day -1 until all study procedures have been 
completed on Day 2. Study drug will be administered on Day 1 of each period at approximately 0800 hours, following 
a 10-hour fast. Dosing may be staggered to help facilitate logistics at the site. Subjects will be instructed to swallow the 
intact capsule with 240 mL of water. On Day 1 of each period, breakfast will not be served. During Periods 1 and 2 of 
each part, blood samples will be collected over 24 hou rs postdose to measure dexlansoprazole plasma concentrations.
A blood sample for pharmacogenomics (PGx) will also be collected on Day 1 of Period 1 of each part. The 
cytochrome P -450 (CYP)2C19 isozyme is a polymorphic enzyme that is involved in the metabol ism of 
dexlansoprazole. A genotype test for CYP2C19 will determine the subject’s metabolizer status.
Subjects will be discharged from the study site on Day 2 of each period (subjects will exit the study on Day 2 of 
Period 2 within each part), and the dosin g between periods within each part will be separated by a minimum 5 -day 
washout interval.
A follow -up phone call will be made 10 (±2) days post last dose of study drug to inquire for any ongoing adverse 
events (AEs) or serious adverse events (SAEs), new AE s or SAEs, and concomitant medications taken since final 
dose. Subjects who withdraw their consent will still be contacted for a safety follow -up call. The contact will only be 
recorded in their source documents and the electronic case report forms (eCRFs) , according to data protection 
regulations.
Primary  completion date will be based on the final data collection for the primary endpoint, Day 2 of Period 2. End of 
trial (study completion date) will be based on the final data collection date for the entire study, which is the follow -up 
phone call.
A schematic of the study design is shown below.
Schematic of Study Design
Screening 
PeriodCheck -in
(Periods 1 
and 2)Treatment Periods 1 and 2
Study Exit 
(Period 2)Follow -up
Phone CallDexlansoprazole 30 
and 60 mg capsule 
Single Dose PKDischarge
(Period 1)
Days -28 to -2 Day -1 Day 1 Day 2 Period 1 Day 2 Day 10 (±2 days)
Confinement 
PK=Pharmacokinetic.
Note: There is a minimum 5-day washout period between the dose in Period 1 and the dose in Period 2. A follow -up 
phone call will be made for collection of AEs, SAEs, and concomitant medications taken since the final dose.
Primary Objectives:
To assess the BA of dexlansoprazole from a 30 mg capsule manufactured at TOB relative to that of 
dexla nsoprazole from a 30 mg capsule manufactured at TPC.
To assess the BA of dexlansoprazole from a 60 mg capsule manufactured at TOB relative to that of 
dexlansoprazole from a 60 mg capsule manufactured at TPC.
Additional Objectives:
To evaluate the safety an d tolerability of dexlansoprazole following oral administration of a single 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 13of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALdexlansoprazole 30 or 60 mg capsule.
Subject Population: Healthy  subjects aged 18 to 55 years, inclusive, who have a body mass index between 18 and 
30kg/m2.
Number of Subjects:
Per dose level: 52
Estimated Total: 104
If additional formulation assessments are required, up to an 
additional 104 subjects will be enrolled.Number of Sites:
Estimated total: 1 in the United States
Dose Level(s):
30mg dexlansoprazole
60mg dexlansoprazoleRoute of Administration:
Oral
Duration of Treatment:
Part 1: Dexlansoprazole 30 mg capsule (manufactured at 
TOB or TPC) administered on Day 1 of Periods 1 and 2.
Part 2: Dexlansoprazole 60 mg capsule (manufactured at 
TOB or TPC) administer ed on Day 1 of Periods 1 and 2.
Total number of dosing days: 2 per Part.Period of Evaluation:
Screening: 27 days.
Check -in (Day -1) for each Period: 2 days total.
Treatment Period (Days 1 to 2) for each Period: 4 days 
total.
Washout between periods: 5 day s.
Follow -up pho ne call: 10 days (±2) after last dose.
Total Study Duration including Screening: 
Approximately 48 days
Main Criteria for Inclusion:
Healthy  men and women aged 18 to 55 years old, inclusive, with a body mass index between 18 and 30 kg/m2, 
inclusive, who are capable of understanding and complying with protocol requirements. Subjects must be in good 
health as determined by a physician based upon medical histor y, vital signs, electrocardiogram (ECG), and physical 
examination. Subjects must have clinical chemistry, hematology, and complete urinalysis (after fasting for at least 
8hours) at Screening and Check -in (Day -1 of Period 1) results within the reference range for the testing laboratory 
unless the out -of-range results are deemed not clinic ally significant by the investigator. Subjects must sign a w ritten 
informed consent form (ICF) prior to initiation of study procedures.
Main Criteria for Exclusion:
The subject has a history of significant gastrointestinal (GI) disorders manifested with persistent, chronic or 
intermittent nausea, vomiting, diarrhea, or has a current or recent (within 6 months) GI disease that would influence 
the absorption of drugs (eg, a history of malabsorption, severe esophageal reflux, peptic ulcer disease or erosive 
esophagitis (EE) with frequent [more than once per week] occurrence of heartburn); or has consumed medications, 
certain foods, and supplements, including prescription and over -the-counter medications, within the 
protocol -specified time periods prior to Che ck-in (Day -1 of Period 1), or is unwilling to agree to abstain from these 
products. The subject must not have received dexlansoprazole in a previous clinical study or as a therapeutic agent 
within 6 months of Screening, or have a known hypersensitivity to any component of the formulation of 
dexlansoprazole capsules or other drugs with the same mechanism of action (including lansoprazole, omeprazole, 
rabeprazole, pantoprazole, or esomeprazole), or related compounds; or any significant results from physical 
examination or clinical laboratory results that make the subject unsuitable for the study.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 14of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALMain Criteria for Evaluation and Analyses:
Primary Endpoints
The primary endpoints for this study are the following plasma PK parameters of dexlansoprazole derived on Day 1 of 
each period:
Maximum observed concentration (C max).
Area under the concentration -time curve from time 0 to time of the last quantifiable concentration (AUC last).
Area under the concentration -time curve from time 0 to infinity (AUC∞).
Additional Endpoints
In addition, the following plasma PK parameters for dexlansoprazole: time to first occurrence of C max(tmax), terminal 
disposition phase half -life (t 1/2z), terminal disposition phase rate constant (λ z), apparent clearance after extravascular 
administration (CL/F), apparent volume of distribution during the terminal disposition phase after extravascular 
administration (V z/F).
Safety Endpoints
Safety will be assessed by summarizing the incidence of AEs, clinical laboratory values, physical examinations, 
ECGs, and vital signs.
Statistical Considerations:
For each regimen of each part, dexlansoprazole plasma concentrations and PK parameter estimates will be tabulated 
and descriptive statistics computed.
For each part, analysis of variance (AN OVA) will be performed on natural logarithms of dexlansoprazole C maxand 
area under the plasma concentration -time curve (AUC) with factors for sequence, subject nested within sequence, 
period, and regimen. The factor of the subject nested within sequence w ill be the erro r term for testing the sequence 
effect. Other factors will be tested with the residual as the error term. For the relative BA determination, pairwise 
comparisons will be performed to assess the relative BA of dexlansoprazole via point estima tes and 90% confidence 
intervals (CI) for the ratio of C maxand AUC central values of the dexlansoprazole 30 or 60 mg capsules manufactured 
at TOB compared to the respective 30 or 60 mg capsules manufactured at TPC. A conclusion of BE in the PK of 
dexlanso prazole between test regimen (dexlansoprazole capsule -TOB) and the reference regimen (dexlansoprazole 
capsule -TPC) will be reached if the 90% CIs for C maxand AUC are within the (0.80 –1.25) interval. 
Statistical analyses of other plasma PK parameters will be performed, if appropriate.
Sample Size Justification:
For each part, a sample size of 52 (26 per sequence) will be used in this study. This sample size will allow for up to 
6dropouts (11.5% dropout rate) and provide 90% probability of concluding equivalence on dexlansoprazole C max
between the 2 regimens if the true difference between dexlansoprazole C maxcentral values from 2 regimens is no more 
than 5%. The power for concluding equivalence on dexlansoprazole AUC between 2 regimens would be over 90%. 
This sample size was based on the intrasubject variance of 0.075 for log(C max) and 0.024 for log(AUC) from the 
TAK -390MR_107 study.
If BE is not achieved with the first TOB formulation assessed, the study may be repeated for one or both dose strengths
in new subjects who will receive the same TOB formulation or a different TOB formulation. The same study design 
will be used if additional formulation assessments are needed.
Dexlansoprazole Delayed-Release Capsules
Study No. TAK-390MR-1001 Page 15 of 82Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL3.0 STUDY REFERENCE INFORMATION
3.1 Study-Related Responsibilities
The sponsor will perform all study-related activities wi th the exception of those identified in the 
Study-Related Responsibilities template. The vendors identified for specific study-related 
activities will perform  these activities in full or in partnership with the sponsor.
3.2 Principal Investigator
Personal Protected Data
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 16of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL3.3 List of Abbreviations
λz terminal disposition phase rate constant
AE adverse event
ALT alanine aminotransferase
ANOVA analy sis of variance
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC∞ AUC from time 0 to infinity
AUC last AUC from time 0 to time of the last quantifiable concentration
BA bioavailability
BE bioequivalence
BMI body mass index
CI confidence interval
CL/F apparent clearance after extravascular administration
Cmax maximum observed concentration
CRO contract research organization
CS clinically significant
CYP cytochrome P -450
DNA deoxyribonucleic acid
ECG electrocardiogram
EDTA ethylenediamine tetraacetic acid
eCRF electronic case report form
EE erosive esophagitis
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GERD gastroesophageal reflux disease
GI gastrointestinal
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HCV hepatitis C virus
HIV human immunodeficiency virus
HRT hormone replacement therapy
IBD international birth date
ICF informed consent form
ICH International Conference on Harmonisation
IEC independent ethics committee
IND Investigational New Drug
INR internatio nal no rmalized ratio
IRB institutional review board
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 17of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALIUD intrauterine device
LFT liver function test
MAV markedly abnormal value
MedDRA Medical Dictionary for Regulatory Activities
MHRA United Kingdom Medicines and Healthcare products Regulator y Agency
NCS not clinically significant
NDA New Drug Application
PGx pharmacogenomics
PK pharmacokinetic(s)
PMDA Pharmaceuticals and Medical Devices Agency  (of Japan)
PPI proton -pump inhibitor
PTE pretreatment event
SAE serious adverse event
SAP statistical analysis plan
SOP standard operating procedure
SUSAR suspected unexpected serious adverse reaction
t1/2z terminal disposition phase half-life
TEAE treatment -emergent adverse event
tmax time to first occurrence of C max
ULN upper limit of normal
US United States
Vz/F apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated using the observed value of the last quantifiable concentration.
WHODRUG World Health Organization Drug Dictionary
3.4 Corporate Identification 
Takeda TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
TDC Americas Takeda Development Center Americas , Inc.
TOB Takeda GmbH Plant Oranienburg, Germany
TPC Takeda Pharmaceutical Company Ltd. (Osaka, Japan)
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 18of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Dexlansoprazole is a proton -pump inhibitor (PPI) with prolonged elevat ion of intragastric pH. 
PPIs inhibit th e secretion of H+ions in the stomach by  inhibi ting the (H+, K+)-ATPase enzyme 
(proton pum p) at the secretory  surface of the gastric parietal cell [1]. Dexl ansoprazol e is the 
R-enantio mer of the racemate lansoprazole. Lansoprazole, init ially approved in France in 1990, is 
currently marketed in over 90 countries and has a well- established safet y profile. 
Takeda Development Center Americas, Inc. (TDC Americas) d eveloped dexlansoprazole 
delayed -release capsules (also referred to as dexlansoprazole modified- release capsules) as a new 
therapy  for treating acid -related di sorders including symptomat ic non -erosive gastroesophageal 
reflux disease (GERD), erosive esophag itis(EE), and maintenance of healed EE and relief o f 
heartburn. Dexlansoprazole capsules are approved for use in adults ( ≥18years of age) and 
adolescents (12 to 17 years of age) in over 35 countries in North and South America, Europe, Asia, 
and the Middl e East. Dexl ansoprazole capsules were first approved for use in adults in the United 
States (US) in January 2009. The internat ional birth date (IBD) is 30 January  2009.
The dual delayed-release capsule formulat ion of dexlansoprazole consists of 2 types of 
enteri c-coated granules contained within a single capsule. Each ty pe of granule has a different 
pH-dependent release profile. The formulat ion has been designed to have drug released wit hin 1 to 
2 hours of administration, fo llowed by  a second release phase within 4 to 5 hours of the dose. This 
dual delayed -release formulat ion is designed to extend the duration of drug exposure and maintain 
pharmaco logically act ive levels of drug over a longer period of time, resulting in pro longed 
elevation of intragastric p H. 
The pharmacokinet ic (PK), pharmacodynamic, efficacy, and safet y profiles of dexlansoprazole 
capsules fo llowing administrati on of  dexlansoprazol e 30, 60, and 90 mg capsules in adults have 
been extensively studied. Dexlansoprazole 60 mg capsules are appr oved for the healing of EE and 
dexlansoprazole 30 mg capsules are approved for the treatment of symptomat ic nonerosive 
GERD, and the maintenance of healed EE. Currently, dexlansoprazole granules (Granules -LL and 
Granules -H for 30 m g and Granules -LS and Gra nules -H for 60 m g) are manufactured and 
encapsulated into capsule product at Takeda Pharmaceut ical Com pany, Ltd. (TPC) located in 
Osaka, Japan.
4.2 Rationale for the Proposed Study
The rati onale for conducting this study  is to qualify an addit ional production site (Takeda GmbH 
Plant Orani enburg [TOB]) for the manufacture of dexlansoprazole capsules by establishing the 
bioequivalence (BE) of dexlansoprazole 30 and 60 mg capsules manuf actured by  TOB wi th 
dexlansoprazole 30 and 60 mg capsules manufactured by the TPC plant in Osaka .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 19of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective(s)
To assess the bioavailabilit y (BA) of dexlansoprazole fro m a 30 mg capsule manufactured at 
TOB relative to that of dexlansoprazole from a 30 mg capsule manufactured at TPC.
To assess the BA of dexlansoprazole fro m a 60 mg capsule manufactured at TOB relat ive to 
that of dexlansoprazole fro m a 60 mg capsule manufactured at TPC.
5.1.2 Additional Objectives
To evaluate the safet y and tol erabili ty of dexlansoprazol e following oral  administrati on of  a 
single 30 mg or 60 mg dexlansoprazole capsule. 
5.2 Endpoints
5.2.1 Primary Endpoints
The fo llowing pl asma PK parameters of dexlansoprazole derived on Day  1 of each period:
Maximum observed concentration (C max).
Area under the concentration -time curve from t ime 0 to time of the last quantifiable 
concentration (AUC last).
Area under the concentration -time curve from t ime 0 to infinit y (AUC∞).
5.2.2 Additional Endpoints
Time to first occurrence of C max(tmax).
Terminal disposit ion phase half -life (t 1/2z).
Terminal disposit ion phase rate constant (λ z).
Apparent cl earance after extravascular administration (CL/F).
Apparent volume o f distribut ion during the terminal disposit ion phase after extravascular 
administration (V z/F).
5.2.3 Safety Endpoints
Safety will be assessed by summarizing the incidence of adverse events (AEs), clinical laboratory 
values, physical examinat ions, electrocardiograms (ECGs), and vital signs.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 20of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL6.0 STUDY DESIGN AND DES CRIPTION
6.1 Study Design
This is a phase 1, randomized, open -label, single -center, single -dose, 2 -part, 2 -way crossover 
study  in healt hy subjects to assess the BA of 30 or 60 mg dexlansoprazole capsules manufactured 
at TOB relat ive to the corresponding 30 or 60 mg dexlansoprazole capsules manufactured at TPC. 
The study  will be conducted in 2 parts. In Part 1, 52 healthy subjects will receive dexlansoprazole 
30mg capsules manufactured by  TOB and TPC in a crossover fashio n. In Part 2, an addit ional 
52healt hy subjects will receive d exlansoprazole 60 mg capsules manufactured by  TOB and TPC 
in a crossover fashio n. Due to the difference between the Granules -L used in the 30 mg 
(Granules -LL) and 60 mg (Granules -LS) capsules, the relat ive BA of both dosage strengths will be 
assessed. If BE is not achieved wit h the first TOB formulat ion, the study  may be repeated for one 
or both dose strengths in new subjects who will receive the same TOB formulat ion or a different 
TOB form ulation. The same study  design will  be used if addit ional form ulation assessments are 
needed.
At Check -in (Day -1 of Period 1), approximately 104 subjects in total (52 in Part 1, 52 in Part 2), 
including both men and women, aged 18 to 55 year s, inclusive, will be selected to participate in the 
study . Subjects who satisfy t he Screening evaluat ion and select ion criteria may be enrolled in the 
study . For each part, eligible subjects will be randomized on Day 1 o f Per iod 1 in a 1:1 ratio to 1 of 
2 sequences, which defines the order in which they will receive dexlansoprazole reg imens in 
Periods 1 and 2. The dosing between periods will be separated by  a minimum  5-day washout 
interval . During Peri ods 1 and 2, bl ood sam ples will  be collected over 24 hours postdose to 
measure dexlansoprazole plasma concentrations. 
The treatment sequ ences are outlined in Table 6.a(Part 1) and Table 6.b(Part 2).
Table 6.a Part 1 Sequences
SequencesNumber of 
Subjects Period 1 Period 2
1 26 A B
2 26 B A
Regimen A (test): A single dexlansoprazole 30 mg capsule manufactured at TOB administered orally on Day  1 
following a 10- hour fast.
Regimen B (reference): A single dexlansoprazole 30 mg capsule manufactured at TPC administered orally on Day 1 
following a 10- hour fast. 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 21of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALTable 6.b Part 2 Sequence s
SequencesNumber of 
Subjects Period 1 Period 2
3 26 C D
4 26 D C
Regimen C (test): A single dexlansoprazole 60 mg capsule manufactured at TOB administered orally on Day 1 
following a 10- hour fast.
Regimen D (reference): A single dexlansoprazole 60 mg capsule manufactured at TPC administered orally on Day 1 
following a 10- hour fast. 
In each period of each part, subjects will be confined fro m Check -in Day -1 unt il all study 
procedures have been co mpleted on Day  2. Study  drug will  be administered on Day  1 of each 
period at approximately  0800 hours, following a 10- hour fast. Dosing may be staggered to help 
facilitate logist ics at the site. Subjects will be instructed to swallow the intact capsule with 2 40 mL 
of water. On Day  1 of each peri od, breakfast will not be served. During Periods 1 and 2, blood 
samples will be co llected over 24 hours postdose to measure dexlansoprazole plasma 
concentrations.
A blood sam ple for pharm acogeno mics (PGx) will also be c ollected on Day  1 of Period1. The 
cytochrom e P-450 (CYP)2C19 isozyme is a polymorphic enzyme that is invo lved in the 
metabo lism of dexlansoprazole. A genotype test for CYP2C19 will determine the subject’s 
metabo lizer status.
Subjects will be discharged fr om the study site on Day 2 of each period (subjects will exit the study 
on Day  2 of Period 2 wi thin each part), and the dosing between periods within each part will be 
separated by  a minimum  5-day washout interval.
A follow-up phone call will be made 10 (± 2) days post last dose of study  drug to inquire for any  
ongoing AEs or serious adverse events (SAEs), new AEs or SAEs, and concomitant medicat ions 
taken since final dose. Any spontaneously reported AEs will continue to be collected for 30 days 
after the l ast dose of study  drug. Subj ects who wi thdraw thei r consent will  still be contacted for a 
safet y follow-up call . The contact will  only  be recorded in their source documents and the 
electroni c case report forms (eCRFs), according to data protection regulat ions.
Primary co mpletion date will be based on the final data collect ion for the primary endpo int, Day 2 
of Period 2. End of tri al (study  com pletion date) will be based on the final data collect ion date for 
the ent ire study , which is the follow -up phone call .
A schemat ic of the study  design is included as Figure 6.aand Figure 6.b. A schedule of 
assessments is listed in Appendix A.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 22of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALFigure 6.a Schematic of Study Design
Screening 
PeriodCheck -in 
(Periods 1 and 2)Treatment Periods 1 and 2
Study Exit 
(Period 2)Follow -Up
Phone CallDexlansoprazole 30 and 60 mg 
capsule
Single Dose PKDischarge 
(Period 1)
Days -28 to -2 Day -1 Day 1 Day 2 Period 1 Day 2 Day 10±2
Confinement 
Note: There is a minimum 5-day washout period between the dose in Period 1 and the dose in Period 2. A follow -up 
phone call will be made for collection of AEs, SAEs, and concomitant medications taken since the final dose.
Figure 6.b Schematic of Crossover Design
PART 1
PART 2
6.2 Justification for Study Design, Dose, and Endpoints
This phase 1 rando mized, open -label, single -dose, 2 -part, 2 -way crossover relat ive BA study  is 
designed in accordance wit h the Bioavailabilit y and Bi oequivalence Studi es Submitted in New 
Drug Applicat ions (NDAs) or Invest igational New Drug (INDs) –General Considerat ions 
Guidance for Industry  (March 2014) [2], and The Committee for Medicinal Products for Human 
Use Guideline on the Invest igation of Bioequivalence (January 2010) [3].
A single -dose study  under fast ing condit ions for assessing the relat ive BA between formulat ions is 
recommended in the guidances referenced above and will be used for comparison of the capsule 
formulations from each manufacturing site. The crossover design is appropriate for the object ives 
of this study  because each subject receives both regimens and serves as his or her own control. 52 subje cts26 planned 
subjects
30 mg TPC
26 planned 
subjects
30 mg TOBwashout
washout26 planned 
subjects
30 mg TOB
26 planned 
subjects
30 mg TPC
52 subjects26 planned 
subjects
60 mg TPC
26 planned 
subjects
60 mg TOBwashout
washout26 planned 
subjects
60 mg TOB
26 planned 
subjects
60 mg TPC
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 23of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALIn humans, de xlansoprazole has a mean t 1/2zof approximately  1 to 2 hours. Therefore, a minimum 
5-day washout interval between the doses is sufficient to ensure that there is no drug carry over 
effect, and collect ion of PK blood samples for 24 hours postdose is appropri ate to characterize the 
PK of dexlansoprazole. The primary PK endpo ints, C maxand area under the concentration -time 
curve (AUC) are standard parameters to assess BA. The safet y endpo ints, including 
treatm ent-emergent adverse events (TEAEs), vital signs, 12 -lead ECGs, clinical laboratory  tests 
and physical examinat ion data, are standard methods for assessing safet y and tol erabilit y in 
clinical pharmaco logy studi es.
The CYP2C19 isozyme is a polymorphic enzyme that is invo lved in the metabo lism of 
dexlansopraz ole. Therefore, the CYP2C19 metabolizer status of the subjects will be determined 
and, if appropriate, the effect of metabo lizer status on the PK o f dexlansoprazole will be assessed. 
As thi s is a crossover study  and each subject will be his/her own control , incl usion of CYP2C19 
poor m etabo lizers is not expected to affect the overall result s of the study .
6.3 Premature Termination or Suspension of Study or Investigational Site
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be completed as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study objectives or compromises subject safet y.
6.3.2 Criteria for Premature Termination or Suspension of Investigational Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwise permitted by  the contractual  agreem ent.
6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site( s)
In the event that the sponsor, an inst itutional review board (IRB), or regulatory  authori ty elects to 
terminate or suspend the study  or the parti cipat ion of an invest igational site, a study -specific 
procedure for early terminat ion or suspensio n will be provi ded by  the sponsor; the procedure will 
be followed by  applicable invest igational sites during the course of terminat ion or study  
suspension.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 24of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be co nfirmed pri or to fi rst dose.
7.1 Inclusion Criteria
Attempts will  be made to enroll an equal number of men and women. Subject eligibilit y is 
determined according to the following criteria prior to entry into the study :
1.In the opinion o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject signs and dates a written, informed consent form and any  requi red privacy 
authori zation prior to the init iation of any study procedures including request ing that a su bject 
fast for any  laboratory  evaluati ons.
3.The subject is in good health as determined by a physician based upon medical history , vital 
signs, ECG, and physical examinat ion findings at Screening and Check -in.
4.The subject is a man or woman aged 18 to 55 yea rs, inclusive, at the time of informed consent 
and first study  medicat ion dose.
5.The subject has a body  mass index (BMI) from 18 to 30 kg/m2, inclusive, at Screening.
6.A man who is nonsterilized* and sexually act ive wit h a wom an of childbearing potential* 
agrees to use adequate contraception* fro m signing of informed consent throughout the 
durati on of  the study  and f or 30 day s after l ast dose of study  drug.
7.A wo man of childbearing potential*who is sexually  active wi th a nonsterilized*male partner 
agrees to routinely use adequate contraception*from signing of informed consent throughout 
the duration of the study , and for 30 day s following the l ast dose of study  drug. Women of 
childbearing potential* must have a negat ive serum pregnancy test at Screening and Check -in 
(Day  -1 of Period 1) and they  must not be nursing.
*Definit ions and acceptable methods of contraception are defined in Sect ion 9.1.9
Contr aception and Pregnancy Avo idance Procedure and reporting responsibilit ies 
are defined in Sect ion 9.1.10 Pregnancy.
8.Subject has clinical chemistry ,hematol ogy, and complete urinalysis (after fast ing for at least 
8hours) at Screening and Check -in (Day -1 of Period 1) results within the reference range for 
the testing laboratory  unless the out -of-range result s are deem ed not clinically  significant by  
the invest igator. 
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study : 
1.The subject has received any invest igational compound wit hin 30 days prior to the first dose of 
study  medicat ion.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 25of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL2.The subj ect has a history  of significant gastrointestinal (GI) disorders manifested with 
persistent, chronic or intermittent nausea, vo miting, diarrhea, or has a current or recent (within 
6 months) GI di sease that woul d influence the absorption of drugs (eg, a his tory of 
malabsorption, severe esophageal reflux, peptic ulcer disease or erosive esophagit is wit h 
frequent [m ore than once per week] occurrence of heartburn). 
3.The subject has a history of drug abuse (defined as any illicit drug use) or drug addict ion in t he 
12 m onths pri or to Screening or a history  of alcohol  abuse (defined as regular consumpt ion 
exceeding 21 units per week [1 uni t = 12 ounces (oz) beer, 1.5 oz hard liquor, or 5 oz wine] ) 
within 1 year pri or to the Screening Visit, or is unwilling to agree to abstain fro m alcoho l and 
drugs throughout the study . 
4.The subject has a posit ive test result for drugs of abuse (defined as any illicit drug use) or 
alcoho l at Screening or Check -in (Day -1 of Period 1). 
5.Subject has received any  known hepat ic or renal clearance al tering agents (eg, ery thromycin, 
cimet idine, barbiturates, phenothiazines, fluvoxamine, etc) for a period of 28 day s prior to 
Day 1 of Period 1. 
6.Subject has had an acute, clinically significant illness within 30 days pri or to Day  1 of 
Period1.
7.Subject has a systolic blood pressure >140 mm Hg or has a diastolic blood pressure 
>90mmHg at Screening or Check -in (Day -1 of Period 1).
8.Subject has a positive test result for hepatit is B surface ant igen (HBsAg), hepat itis C virus 
(HCV) antibody at Screening or a known history of human immunodeficiency virus infect ion 
(HIV).
9.Subject has abnormal Screening or Day  -1 of Period 1 laboratory  values that suggest a 
clinically significant underlying disease or subject with the following lab abnormalit ies: 
creatinine >1.5 mg/dL, alanine aminotransferase (ALT) and or aspartate aminotransferase 
(AST) >2.5 x the upper limit of normal (ULN) or total bilirubin >2.0 mg/dL.
10.Subject has an abnormal (clinically significant) ECG at Screening or Check -in (Day -1 of 
Period 1). Entry  of any subject wi th an abnorm al (not clinically significant) ECG must be 
approved, and documented by  the signature of the principal investigator.
11.Subject has donated blood products (such as plasma) within 30 days or has donated whole 
blood or l ost 450 mL or more of his or her blood volume, or had a transfusio n of a ny bl ood 
product within 56 days prior to Day  1 of Period 1.
12.With the exception o f acetaminophen, the subject has taken any excluded medicat ion, 
supplements, or food products listed in Section 7.3. Horm onal contracepti on and horm one 
replacement therapy  are all owed, as l ong as the subject has been on a stable dose for a 
minimum o f 90 day s prior to Day  1 of Period 1.
13.Subject has used nicotine -containing products (including but not limited to cigarettes, pipes, 
cigars, chewing tobacco, nicotine patch nicotine gum, e -cigarettes) wi thin 28 days pri or to 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 26of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALCheck -in (Day -1 of Period 1), or has a posit ive cotinine test at Screening or Check -in (Day -1 
of Period 1), or i s unwilling to abstain from these products for the durati on of  the study .
14. The subject has received dexlansoprazole or lansoprazole in a previous clinical study or as a 
therapeuti c agent wi thin 6 m onths of screening.
15.The subject has a history  (within 6 m onths) or clinical manifestations of clinically  signif icant 
metabo lic, hematologic, pulmo nary, cardi ovascular, gastrointestinal, neurologic, hepat ic, 
renal, urologic, immuno logic, muscul oskeletal  or psychiatri c disorder as defined by  the 
investigator, which may impact the abilit y of the subject to participate or potentially confound 
the study  resul ts.
16.Subject has a history  of cancer, except basal cell carcinoma that has been in remissio n for at 
least 5 y ears pri or to Day  1 of Period 1.
17.The subject has poor peripheral venous access.
18.Subject has a known hypersensit ivity to any  component of the formulat ion of dexlansoprazole 
capsules or other drugs with the same mechanism of action (including lansoprazole, 
omeprazo le, rabeprazo le, pantoprazole, or esomeprazole), or related compounds.
19.If a woman, the subjec t is pregnant or lactating or intending to become pregnant before, during, 
or wi thin 30 days after participat ing in this study , or intending to donate ova during such time 
period. 
20.If a man, the subject intends to donate sperm during the course of this stu dy or for 30 days 
thereafter.
21.The subject is an immediate family member, study site emplo yee, or i s in a dependent 
relationship with a study  site em ployee who i s involved in the conduct of this study  
(eg,spouse, parent, child, sibling) or may consent unde r duress .
7.3 Excluded Medications and Dietary Products
Use of the agents in Table 7.a(prescri ption or nonprescri ption) is prohibited fro m the time points 
specified and for the durati on of  the subject’s participat ion in the study . 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 27of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALTable 7.a Prohibited Medications, Supplements, and Dietary Products
28 days prior to Check -in (Day -1 of 
Period 1)7 days prior to Check -in (D ay-1 of 
Period 1)72 hours prior to Check -in 
(Day -1 of Period 1)
Prescription medications including 
oral contraceptives (a)OTC medications ( b) Alcohol -containing products
Nicotine-containing products Vitamin supplements
Nutraceuticals (eg, St. John’s wort, 
ginseng, kava kava, ginkgo biloba, 
Chinese herbs, and melatonin)Foods or beverages containing grapefruit 
or grapefruit juice, star fruit or star fruit 
juice, Seville -type (sour) oranges and 
marmalade, apple, orange, or pineapple 
juice, vegeta bles from the mustard green 
family  (eg, kale, broccoli, watercress, 
collard greens, kohlrabi, Brussels 
sprouts, mustard), and charbroiled meatsProducts containing caffeine 
and/o r xanthine
Hepatic or renal clearance altering 
agents
Immunization/Vaccines (c)Intake of known OTC inhibitors/inducers 
of CYPs 3A4/5, 2C9, 2C19, 2D6, 1A2, 
2B6, 2E1, and 2A6 (d)Poppy seeds
OTC=over -the-counter.
(a) Hormonal contraception and hormone replacement therapy (HRT) are allowed, as long as the subject has been on a 
stable dose for a minimum of 90 days prior to Day 1.
(b) Occasional use of acetaminophen (≤2 g/day) is allowed or other medication as approved by Takeda on a 
case-by-case basis. Acetaminophen is not allowed on Day 1.
(c) Inclusive of but not limited to H1N 1 and flu vaccinations.
(d) Lansoprazole, esomeprazole, omeprazole, cimetidine, ranitidine, and chlorpheniramine.
Subjects m ust be instructed not to take any  medicati ons including over -the-counter products, 
without fi rst consul ting wi th the investi gator du ring the Washout Period, as well as during 
confinement.
7.4 Diet, Fluid and Activity Control 
7.4.1 Confinement
Subjects enrolled in this study will be confined in the clinical research unit for 2 consecutive nights 
in each period, beginning at Check- in (Day -1) to Day 2. There will be a minimum 5 -day washout 
interval  between the dose in the first period and the dose in the second period. Subjects will be 
released from  the clinic during the washout interval.
7.4.2 Diet and Fluid
During each day  of the confinement period, s ubjects will receive standardized meals and an 
evening snack, each of which contains approximately 30% fat (caloric value). The clinical 
research site will ensure the same meals are served to all subjects on Day  1 of both study  periods. 
All subjects m ay co nsume water ad libitum except for 1 hour before and 1 hour after drug 
administration. 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 28of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALDuring confinement, foods and beverages listed in Table 7.awill be prohibited, and all subjects 
will be limited to only standardized meals and snacks provided by the site.
Subjects will fast for a minimum o f 10 hours prior to dosing on Day 1 of each period. On Day 1 of 
each peri od, breakfast will not be served. Lunch will be served approximately  4hours postdose. 
Dinner will be served approximately 9 hours postdose. A snack will be served approximately 
12hours postdose. No addit ional meals will be served on Day 1 of each period. The start and stop 
times of meals on D ay 1 of each peri od, al ong wi th whether the meal was completely  consumed, 
will be recorded in the source documentation and on the eCRF. Subjects will be fast ing for a 
minimum of 8 hours prior to collect ion of safety labs and 24 hour PK sample on Day 2 of P eriods 1 
and 2.
7.4.3 Activity Control
Subjects should be instructed to refrain fro m strenuous exercise starting approximately 48 hours 
prior to confinement on Day  -1 of Period 1 and for the duration of their participat ion in the study . 
7.5 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study 
medicat ion shoul d be recorded in the eCRF using the fo llowing categori es. For screen failure 
subjects, refer to Section 9.1.15 .
1.Pretreatment event or AE. The subject has experienced a pretreatment event or AE that 
requi res early  terminat ion because continued part icipation imposes an unacceptable risk to the 
subject’s healt h or the subject is unwilling to continue because of the pretreatment event or AE.
Liver Funct ion Test (LFT) Abnormalit ies 
Study  medicati on shoul d be discont inued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 9.1.8 ), if the fo llowing circumstances occu r at any time 
during study  medicat ion treatment: 
–ALT or AST >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or 
internat ional norm alized rati o (INR) >1.5, or ALT or AST >3 × ULN with appearance 
of fatigue, nausea, vo miting, right upper quadrant pain or tenderness, fever, rash and/or 
eosinophilia (>5%).
2.Significant protocol  deviat ion. The discovery  after the first dose of study  medicat ionthat the 
subject failed to meet protocol  entry  criteria or di d not adhere to protocol requirements, and 
continued participation poses an unacceptable risk to the subject’s health.
3.Lost to follow -up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 29of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL4.Voluntary  withdrawal. The subject wishes to withdraw from the study . The reason for 
withdrawal , if provi ded, shoul d be recorded in the eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an 
AE).
5.Study  terminat ion. The sponsor, IRB, or regulatory agency terminates the study.
6.Pregnancy. The subject is found to be pregnant. 
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.10 .
7.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subj ect meets the study termination criteria described in Section 7.5.
 In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addit ion, efforts should be made to perform all procedures scheduled for the 
Early Terminat ion Visit. Di scont inued or withdrawn subjects may be replaced.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 30of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL8.0 CLINICAL TRIAL MATER IAL MANAGEMENT
This sect ion contains informat ion regarding all medicat ion provi ded di rectly by  the sponsor, 
and/or sourced by  other m eans, that are required by  the study  protocol , incl uding important 
sections describing the management of clinical trial material.
8.1 Study Medication
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s protocol , the term  study  medicat ion refers to all or any  of the drugs defined below.
The study  site will  be supplied wit h 30-count bottles of dexlansoprazole delayed -release capsules 
30mg manufactured at TOB (containing Granules -LL and Granules -H), and 30 mg capsules 
manufactured at TPC ( containing Granules -LL and Granules -H). Also suppli ed will be 30- count 
bottles of dexlansoprazole delayed- release capsules 60 mg manufactured at TOB (containing 
Granules -LS and Granules -H), and 60 mg capsules manufactured at TPC (containing Granules -LS 
and Granules -H).The bottl es will be packaged in an open label manner. The bottles will bear a 
single- panel com puter -generated label containing the required informat ion, including the Federal 
cauti on statem ent “CAUTION: New Drug- Limited by  Federal  (or Uni ted States) Law to 
Invest igational Use.” 
The sponsor w ill supply the site wit h study  drug as shown in Table 8.a.
Table 8.a Study Medication –Sponsor Supplied
Formulation Investigational Product Dosage Manufacturer and Location
A (test) Dexlansoprazole capsule 30mg Capsules manufactured at TOB
B (reference) Dexlansoprazole capsule 30mg Capsules manufactured at TPC
C (test) Dexlansoprazole capsule 60mg Capsules manufactured at TOB
D (reference) Dexlansoprazole capsule 60mg Capsules manufactured at TPC
8.1.2 Storage
All drug supplies used to conduct this study must be kept in an appropriate, limited -access, secure 
place unt il it is used or returned to the sponsor or designee for destruction. Drug supplies must be 
stored at controlled room temperature 20°C to 25°C (68°F to 77°F; see US Pharmacopeia); 
excursio ns allowed between 15°C and 30°C (59°F to 86°F), protected from mo isture and in a 
secure l ocati on until dispens ed to study  subjects or returned to Takeda or its designee. Drug 
supplies will be counted and reconciled at the site before disposit ion or return to Takeda or 
designee. Each drug supply  must be returned in its original container.
8.1.3 Dose and Regimen
Subjects will fast for a minimum o f 10 hours prior to dosing in Periods 1 and 2. On Day  1 at 
approximately  0800 hours, subjects will be instructed to swallow the intact capsule with 240 mL of 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 31of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALwater. Dosing may be staggered to help facilitate logist ics at t he site. All subjects may consume 
water ad libitum, except for 1 hour prior to and 1 hour post drug administration. Subjects must 
drink all o f the water provided wit h the dose.
Following the administration o f the study  drug, hand and mouth checks will be p erformed to 
ensure the dose was swallowed. Alt hough the timing of events requires that each subject will be 
consistent ly ad ministered the appropriate dose at specific times, the exact dose time of consecut ive 
subjects may  be staggered to obviate the need to have all subjects on precisely  the same study  
schedule.
On each dosing day  (Day 1 of Peri ods 1 and 2) subjects will be administered dosing regimens 
according to the sequence group they  are assi gned to (See Table 8.b).
The 4 dosing regimens are:
Regimen A: A single 30 mg dexlansoprazole capsule manufactured at TOB.
Regimen B: A single 30 mg dexlansoprazole capsule manufactured at TPC.
Regimen C: A single 60 mg dexlanso prazol e capsule manufactured at TOB.
Regimen D: A single 60 mg dexlansoprazole capsule manufactured at TPC.
On Day  2 of Period 1, subjects will be discharged from the study  site for a minimum washout 
interval  of 5 day s between the dose in the first period and the dose in the second period. 
Table 8.b Dose and Regimen
Study Part Sequence Number of SubjectsPeriod 1
RegimenPeriod 2
Regimen
Part 1
30mg1 26 A B
2 26 B A
Part 2
60mg3 26 C D
4 26 D C
Regimen A: A single 30 mg dexlansoprazole capsule manufactured at TOB administered orally on Day 1 following a 
10-hour fast.
Regimen B: A single 30 mg dexlansoprazole capsule manufactured at TPC administered orally on Day 1 following a 
10-hour fast. 
Regim en C: A single 60 mg dexlansoprazole capsule manufactured at TOB administered orally on Day 1 following a 
10-hour fast.
Regimen D: A single 60 mg dexlansoprazole capsule manufactured at TPC administered orally on Day 1 following a 
10-hour fast. 
Note: If t he study  is repeated in the same or new formulations, the regimens will be labeled AA, BB, CC, and DD, as 
needed.
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of invest igational drug, 
to or by a study subject, at a dos e above that which is assigned to that individual subject according 
to the study  protocol .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 32of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAll cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information cons istent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on AE eCRF(s) according to Section 10.0, Pretreatm ent 
Events and Adverse Events.
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.2.2 ,
 Collect ion and Reporting of SAEs.
In the event of drug overdose, the subject should be treated symptomat ically by  the invest igator.
8.2 Investigational Drug Assignment and Dispensing Procedures
Subjects will be ass igned, in the order in which they are rando mized into the study, to receive their 
treatm ent according to the randomizat ion schedule allocated to the site. The Randomization 
Sequence Number will be entered onto the eCRF.
Subjects will be assigned to receive a 4-digit randomizat ion sequence number by the clinic site 
personnel in sequent ial order. For Part 1, m en will be assigned in ascending order starting from 
1001 and women will be assigned in descending order starting from 1052. For Part 2, men will be 
assigned in ascending order starting fro m 2001 and wom en will be assigned in descending order 
starting from 2052. Addit ional schedules will be generated if the second formulat ions are assessed. 
This 4 -digit number will be used by the clinical site to facilita te the prelabeling of PK samples, and 
will be the only subject ident ifier used on all PK sample collect ions. It should also be contained on 
the PK transport vials shipped to the bioanalyt ical laboratory, and will be used by the laboratory to 
report the sub ject data results. This 4- digit number shoul d only be used for the purposes described 
in this sect ion. It does not replace the 3- digit subject number which is assigned at the time the 
inform ed consent i s obtained and which is used for all other procedures to identify the subjects 
throughout the study .
8.3 Randomization Code Creation and Storage 
The rando mizat ion schedule will be generated prior to the start of the study , and will be provided 
to the site pharmacist prior to the start of this study. All rando mization informat ion will be stored 
in a secured area, accessible only by  authori zed personnel.
8.4 Accountability and Destruction of Sponsor- Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee.
The investigator or designee must ensure that the sponsor -supplied drug is used in accordance wit h 
the protocol and is dispensed only to subjects enro lled in the study . To docum ent appropri ate use 
of sponsor -supplied drug, the invest igator or designee must maintain records of all 
sponsor -supplied drug delivery to the site, site inventory , dispensation, use by  each subject, and 
return to the sponsor or designee.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 33of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALUpon receipt of sponsor -supplied drug, the invest igator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and the 
medicat ion is in good condit ion. If quant ity and condit ions are acceptable, invest igator or designee 
shoul d acknowl edge the receipt of the shipment by si gning the bottom half o f the packing list and 
faxing per instructions provided on the form. If there are any  discrepancies between the packing 
list versus the actual product received, Takeda must be contacted to resolve the issue. The packing 
list sho uld be filed in the invest igator’s essent ial docum ent file.
The invest igator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her entire participat ion in the study . Proper drug 
accountabilit yincludes, but is not limit ed to:
Continuously mo nitoring expiration dates if expiry date is provided to the invest igator or 
designee.
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the log is completed for the drug lot used to prepare each dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be noti fied immediately.
The invest igator or designee must record the current inventory of all sponsor -supplied drugs on a 
sponsor -approved drug accountabilit y log. The fo llowing informat ion will be recorded at a 
minimum: protocol number and tit le, name of invest igator, site ident ifier and number, descript ion 
of sponsor -supplied drugs, expiry date and amount dispensed, including init ials of the person 
dispensing the drug, and the date and amount returned to the site by  the subject, including the 
initials of the pe rson receiving the sponsor -supplied drug. The log should include all required 
inform ation as a separate entry  for each subject to whom sponsor -supplied drug is dispensed.
All study  drug that was not returned to the site by  a subject m ust be invest igated by the site and 
appropriately  docum ented on the drug accoun tability  log.
Prior to si te closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied 
drugs are returned to the sponsor or its designee for destruction. The invest igator or designee will 
retain the original documentation regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and copies will be sent to the spons or or desi gnee.
The invest igator will be notified of any expiry date or retest date extensio n of sponsor -supplied 
drug during the study conduct. On expiry date notificat ion from the sponsor or designee, the site 
must com plete all  instructi ons outlined in t he notification, including segregat ion of expired 
sponsor -supplied drug for return to the sponsor or its designee for destruction.
In the event of expiry date extensio n of supplies already  at the study  site, clinical study material
may be relabeled wit h the new expiry date at that site. In such cases, Takeda or its designee will 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 34of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALprepare addit ional labels, and all necessary  documentati on for com pletion of the procedure at the 
sites.
8.5 Reserve Study Medication Samples for Retention
Theinvestigator will retain a reserve sample of dexlansoprazole capsules in accordance with Food 
and Drug Administration (FDA) regulat ions. The investigator or the invest igator’s designee will 
select the appropriate number of containers of study medicat ion for retenti on, as specified in the 
bioretent ion letter to be provided by  Takeda Clinical  Supplies. Reserve samples will be stored 
under condit ions consistent with the product’s labeling and in a segregated area with access 
limited to authorized personnel. E ach reserve sample will be retained for a period of at least 5 years 
following the date the applicat ion or supplemental applicat ion is approved by the FDA. If the 
applicat ion is not approved, regulat ions specify that these samples must be stored for at lea st 5 
years fo llowing the date of complet ion of this BA study. The clinical site should not dispose of the 
reserve samples without written authorization fro m Takeda. If at any time the invest igator is 
unable to comply with these requirements, the investigat or shoul d immediately notify Takeda 
regarding arrangements for storing reserve samples and associated study  records on the 
investigator’s behalf.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 35of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.0 STUDY PLAN
9.1 Study Procedures
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same invest igator or site personnel whenever possible. The 
Schedule of Study  Procedures i s located in Appendix A.
9.1.1 Informed Consent Procedure
The requi rements of the informed consent are described in Sect ion
 15.2.
Inform ed consent m ust be obtained prior to the subjec t entering into the study , and before any 
protocol -directed procedures are performed, including requesting that a subject fast for laboratory 
evaluat ions.
A unique subject ident ificat ion number (subject ID = site + subject number) will be assigned to 
each subject at the time that informed consent is obtained; this subject number will be used 
throughout the study .
9.1.1.1 Pharmacogenomic Informed Consent Procedure
PGx informed consent is a co mponent of the overall study informed consent. The requirements are 
describ ed in Section 15.2.
 The PGx sample collect ion is mandatory.
9.1.2 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth, gender, Hispanic ethnicit y, 
race as described by the subject ,height, weight, caffeine consumption, xanthine consumpt ion, 
alcoho l use, reproductive status (including last menstrual period) and smoking status of the subject  
at Screening.
Medicat ion history  informat ion to be obtained includes any medicat ion relevant to eligibilit y 
criteria stopped at or within 28 days prior to signing of informed consent.
Medical history  to be obtained will include determining whethe r the subject has any  significant 
condi tions or di seases rel evant to the di sease under study  that resolved at or prior to signing of 
inform ed consent. Ongoing condit ions are considered concurrent medical condit ions (see 
Secti on9.1.7 ).
9.1.3 Physical Examination Procedure
Physical exams will be performed at Screening, Check -in (Day -1 of Periods 1 and 2), Day 2 Study 
Exit for Peri od 2 only , Early Terminat ion, and during Unscheduled Visit s. A baseline physical 
examinat ion (defined as the pretreatment assessment immediately prior to the start of study  drug) 
will be performed at Check -in (Day -1) of Peri od 1. The exams will consist of the fo llowing body 
system s: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory  system; 
(5)gastrointestinal system; (6) dermatologic system; (7) extremit ies; (8) musculoskeletal system; 
(9) nervous sy stem; (10) lymph nodes; (11) genitourinary  system; and (12) other. The 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 36of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALgenitourinary  examinat ion will no t be required for this protocol but will be listed on the eCRF page 
for physical  examinat ion and hard -coded as “not done.”
All physical examinat ions subsequent to Check -in (Day -1) of Peri od 1 shoul d assess clinically 
significant changes fro m the Baseline Check -in (Day -1) of Period 1 examinat ion. If a body syste m 
is not examined, “not done” should be indicated.
Any abnormal finding on a pretreatment physical examinat ion assessment must be assessed as not 
clinically significant (NCS) or clinically significant (CS) by  the invest igator and recorded in the 
source document and eCRF. All CS findings/changes will be recorded as a pretreatment event 
(PTE) or concurrent medical condit ion in the source document and on the appropri ate eCRF
described in Section 10.0 or Section 9.1.7 .
On subsequent examinat ions, any  abnorm al change from  the pretreatm ent phy sical examinat ion 
assessment occurring immediately  prior to the start of the study  drug must be assessed as NCS or 
CS by  the invest igator and recorded in the source document and eCRF. Any CS change or new 
diagnosis as a result of a CS change, as determined by  the invest igator, will be recorded as an AE 
in source documentation and on the PTE/AE eCRF described in Sect ion 10.0.
9.1.4 Weight, Height and BMI
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. The BMI is calculated using metric unit s with the form ula pr ovided bel ow. The Takeda 
standard for collecting height is cent imeters without decimal places and for weight it is kilograms 
(kg) wi th 1 decimal place. BMI should be derived as:
Metri c: BMI = weight (kg)/[hei ght (m )]2
Note that although height is reported in centimeters, the formula uses meters for height; meters can 
be determined from cent imeters by dividing by 100. For example, if weight=79.2 kg and 
height=176 cm (1.76 meters), then BMI=79.2/1.762=25.56818 kg/m2.
The values should be reported to 1 decima l place by rounding. Thus, in the above example BMI 
woul d be reported as 25.6 kg/m2. 
However, if the BMI is used as entry  criteria based on 30 kg/m2
cut-off point, then this determinat ion must be made after rounding.
9.1.5 Vital Sign Procedure
Vital signs will include oral body temperature, sitting blood pressure (resting 5 minutes), and pulse 
(beats per minute). Only  blood pressure and pulse will be taken on Check -in (Day -1) through 
Day 2. Vi tal signs will be obtained at the time points stipulated in Schedule of Study  Procedures 
(Appendix A). 
When vital signs are scheduled at the same t ime as blood draws, the blood draw will take priorit y 
and vital signs will be obtained wit hin 0.5 hour before or after the scheduled blood draw.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 37of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.1.6 Documentation of Concomitant Medications
Subjects will be instructed not to take any  medicat ions during the study, including 
over-the-counter products, without first consult ing with the invest igator. Use of conco mitant 
medicat ions will not be allowed during the study  unless deemed necessary  in cases of medical 
emergency or approved by  the sponsor on a case -by-case basis. Occasio nal use o f acetaminophen 
(up to 2 g/day) is allowed. Acetam inophen is not allowed on Day  1 of each peri od. Horm onal 
contraception and HRT are allowed, as long as a subject has been on a stable dose for a minimu m 
of 90 day s prior to Day  1.
All medications used within 28 days prior to Screening will be recorded in t he source document 
and Medication History  eCRF. All medications taken from Screening through to the end of the 
study  will be recorded in the source document and Concomitant Medication eCRF.
9.1.7 Documentation of Concurrent Medical Conditions
Concurrent medical condi tions are those significant ongoing condit ions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory , ECG, or phy sical 
examinat ion abnormalit ies noted at the Screening examinat ion. The condit ion (ie, diagnosis) 
shoul d be described.
9.1.8 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptable laboratory  procedures. Laboratory  
samples will be taken fo llowing a minimum 8 -hour overnight fast at the time points stipulated in 
the Schedule of Study  Procedures ( Appendix A).
Table 9.alists the tests that will be obtained for each laboratory  specimen.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 38of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALTable 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
RBC
WBC with differential 
Hemoglobin
Hematocrit
PlateletsAlanine aminotransferase 
Albumin
Alkaline phosphatase
Aspartate aminotransferase
Glucose
Total bilirubin
Total protein
Total cholesterol
Triglycerides
Serum creatinine
Blood urea nitrogen
Uric acid
gamma -glutamyl transferase
Calcium
Phospho rus
Potassium
Sodium
Chloride
Bicarbonate or carbon dioxideSpecific gravity
pH
Protein
Ketones
Glucose
Bilirubin
Red blood cells and white 
blood cells
Microscopic battery 
(RBCs, WBCs, epithelial 
cells, casts) if significant 
findings on dipstick 
urinaly sis
Diagnostic Screenings:
Serum Urine/Blood Breath
Hepatitis panel, including HBsAg
and anti -HCVDrug screen, including amphetamines, barbiturates, 
benzodiazepines, cannabinoids, cocaine, cotinine 
and opiates.Alcohol
Women subjects only:
Serum hCG for pregnancy
Serum FSH If postmenopausal women 
defined as amenorrhea >1 year
FSH=follicle stimulating hormone, hCG= human chorionic gonadotropin, RBC=red blood cells, WBC=white blood 
cells.
The l ocal laboratory  will perform laboratory  tests for hem atology, serum  chemistri es, and 
urinalysis as referenced in Appendix A. The resul ts of laboratory  tests will be returned to the 
investigator, who is responsible for filing and reviewing these results for clinical significance 
together wi th the data in the eCRF. 
Laboratory  reports m ust be signed and dated by  the principal invest igator or subinvestigator 
indicat ing that the report has been reviewed and any abnormalit ies have been assessed for clinical 
significance. All clinically  significa nt laboratory  abnorm alities m ust be recorded as an AE in the 
subject’s source documents and on the appropriate eCRF unless they are the result of pathology for 
which there is an overall diagnosis. The investigator will maintain a copy  of the l aboratory  
accreditation and the reference ranges for the laboratory  used. A clinically significant laboratory  
abnorm ality that has been verified by retesting will be fo llowed unt il the abnormalit y returns to an 
acceptable level or a satisfactory  explanat ion has been ob tained. 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 39of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.1.9 Contraception and Pregnancy Avoidance Procedure
From  signing of informed consent, throughout the duration of the study , and for 30 days after last 
dose of study  medicat ion, nonsterilized wo men of childbearing potential* who are sexually active 
with a nonsterilized male partner** must use adequate contraception. In addit ion they  must be 
advised not to donate ova during this period.
From  signing of informed consent, throughout the duration of the study , and for 30 days after last 
dose of study  medica tion, nonsterilized** men who are sexually  active wit h a wom an of 
childbearing potential* must use barrier contraceptio n (eg, condom wit h spermicidal cream or 
jelly). In addition they must be advised not to donate sperm during this period.
*Wo men of childb earing potenti al are defined as any  female who has experienced menarche and 
who are NOT permanent ly sterile or postmenopausal. Wo men NOT of childbearing potential are 
defined as those who have been surgically sterilized (hysterectomy , bilateral  oophorectom y or 
tubal  ligation) or who are postmenopausal (eg, defined as 12 consecut ive months with no menses 
without an al ternat ive medical cause).**Sterilized men should be at least 1 y ear postvasectomy  
and have confirmed that they  have obtained documentation of t he absence o f sperm  in the 
ejaculate.
An acceptable method of contraception is defined as one that has no higher than a 1% failure rate. 
In thi s study , where medicat ions and devices containing hormones are included, the only 
acceptable methods of contracepti on are:
Barrier methods (each time the 
subject has intercourse):Intrauterine devices 
(IUDs): Hormonal contraceptives:
Male condom PLUS 
spermicide.
Cap (pl us spermicidal cream or 
jelly) PLUS male condom.
Diaphragm  (plus spermicidal 
cream  or jelly) PLUS male 
condom .Copper T PLUS 
condom  or spermicide.
Progesterone T PLUS 
condom  or spermicide.Implants.
Horm one shot/i njecti on.
Combined pill.
Minipill.
Patch.
Vaginal ring PLUS male 
condom  and spermicide.
Subjects will be provided with information on acceptabl e methods of contraception as part of the 
subject informed consent process and will be asked to sign a consent form stating that they  
understand the requirements for avo idance o f pregnancy and donat ion of ovaand sperm during the 
course of the study .
At Screening, serum hCG pregnancy tests will be performed only for women of childbearing 
potenti al and subjects will receive continued guidance with respect to the avoidance of pregnancy 
and ova and sperm  donat ion as part of the study  procedures ( Appendix A). In addi tion, subjects 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 40of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALmust al so have a negative serum hCG pregnancy  test 1 day  prior to receiving first dose of study  
medicat ion.
9.1.10 Pregnancy
If any subject is found to be pregnant during the study , she shoul d be wi thdrawn and any  
sponsor -supplied drug should be immediately discontinued. In addit ion, any pregnancies in the 
partner of a male subject during the study or for 30 days after the last dose should also be recorded 
following authori zation from the subject’s partner.
If the pregnancy  occurs during administration of active study  medicat ion, eg, after Check- in 
(Day -1 of Period 1) or wi thin 30 days of the l ast dose of active study  medicat ion, the pregnancy  
should be reported immediately, using a pregnancy notificat ion form, to the contact listed in 
Secti on 1.0.
If the woman agrees to the primary  care ph ysician being informed, the invest igator should notify 
the primary  care physician that the subject was participat ing in a clinical study at the time she 
became pregnant and provide details of treatment the subject received (blinded or unblinded, as 
applica ble).
All reported pregnancies will be fo llowed up to final outcome, using the pregnancy form. The 
outcom e, including any  premature terminat ion, must be reported to the sponsor. An evaluat ion 
after the bi rth of  the child will also be conducted.
9.1.11 ECG Procedu re
A standard 12- lead ECG will be recorded at Screening, Check -in (Day -1) of
 Period 1, and Day  2 
Study  Exit of Periods 1 and 2 or if a subject terminates early fro m the study. The invest igator (or a 
qualified observer at the invest igational site) will int erpret the ECG using 1 of the fo llowing 
categori es: within normal limits, abnormal but not clinically significant, or abnormal and clinically 
significant. The results of the ECG will be captured on the source documents and appropriate 
eCRF and the original hard copi es shoul d be kept as source documentation. ECGs on thermal 
paper must be photocopied and the copy  shoul d be kept in the subjects’ source documents. The 
following parameters will be recorded on the eCRF from the subject’s ECG trace: heart rate, QT
interval , and QRS interval.
9.1.12 Pharmacogenomic Sample Collection
When sampling of who le blood for PGx analysis occurs, every subject must sign an informed 
consent/be consented in order to participate in the study .
Deoxy ribonucleic acid (DNA) form the basis f or the genes that make the body  produce proteins 
such as enzymes, drug transporters or drug targets, and may be evaluated for the genet ic 
contribution how the drug is broken down, or how the drug affects the body. This is called a “PGx 
research study .” Spe cific purposes of this study  include:
Identifying genet ic reasons certain people respond different ly to dexlansoprazole.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 41of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALFinding out more informat ion about how dexlansoprazole works.
Generat ing informat ion needed for research, development, and regulatory  approval  of tests to 
predi ct response to dexlansoprazole.
Ident ifying variations in genes related to the bio logical target of dexlansoprazole.
This information may be used to develop a better understanding of the safet y and efficacy  of 
dexlansoprazole and other study  medicat ions, and for improving the efficiency, design, and study  
methods of future research studies.
One 6 mL who le blood sam ple for DNA i solation will be co llected before dosing on Day 1 of 
Period 1 f rom each subject in the study , into pl asticK2 ethylenediamine tetraacetic acid (EDTA) 
spray -coated tubes, and stored under frozen condit ions. If necessary and feasible, a second aliquot 
of blood may  be taken at any  time after randomizatio n if isolation of DNA from the first sample 
was not successf ul or possible.
The samples will be stored for no l onger than 15 years after complet ion of the dexlansoprazole
study  and/or until the drug development of dexlansoprazole is no longer actively pursued by 
Takeda or i ts collaborators. No sam ples will be store d for l onger than permitted by  the applicable 
law and samples will be destroyed upon notificat ion fro m Takeda. “Stored samples” are defined as 
samples that are key -coded (the samples are stripped of all personal ident ifying informat ion but a 
key links the samples to the clinical data collected fro m the sample donor) and are used in the 
analysis of invest igational drug or related drugs.
The CYP2C19 isozyme is a polymorphic enzyme that is invo lved in the metabo lism of 
dexlansoprazole. Therefore, the CYP2C19 m etabolizer status of the subjects will be determined.
Detailed instructions for the handling and shipping of samples are provided in the Lab Manual.
9.1.13 PK Sample Collection
9.1.13.1 Collection of Blood for PK Sampling
Blood sam ples (4 mL) for dexl ansoprazole pl asma c oncentrations will be co llected beginning on 
Day 1 of each peri od of  each part, as shown in Table 9.b.
Instructi ons for sam ple processing and shipment are provided in Appendix E.
Table 9.b Collection of Blood Samples for PK Analysis
Sample 
TypeDosing Day
Time (hour s) (Periods 1 and 2)
Plasma 1 Predose (within 15 minutes prior to dose) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 
10, 12, 16, and 24 hours postdose.
The actual  time of sample co llection will be recorded on the source document and eCRF. The PK 
sample shoul d not be collected at the Early Termination Visit if a PK collection is not scheduled.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 42of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.1.14 PK Parameters
Plasma PK parameters of dexlansoprazole will be derived using nonco mpart mental analysis 
methods. The PK parameters of dexlansoprazole will be determin ed from the concentrati on-time 
data for all evaluable subjects. Actual sampling times, rather than scheduled sampling times, will 
be used in all PK co mputations invo lving blood sampling times. The fo llowing PK parameters for 
dexlansoprazole will be determi ned. Addit ional PK parameters may be calculated as appropriate.
Symbol/Term Definition
Plasma
AUC last Area under the concentration -time curve from time 0 to time of the last quantifiable 
concentration.
AUC ∞ Area under the concentration -time curve from time 0 to infinity, calculated using the observed 
value of the last quantifiable concentration.
Cmax Maximum observed concentration.
CL/F Apparent clearance after extravascular administration, calculated using the observed value of 
the last quantifiable concentration.
λz Terminal disposition phase rate constant.
t1/2z Terminal disposition phase half -life.
tmax Time of first occurrence of C max.
Vz/F Apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated using the observed value of the last quantifiable concentration.
9.1.15 Documentation of Screen Failure
Invest igators must account for all subjects who sign informed consent. If the subject is found to be 
not eligible at this visit, t he invest igator should complete the eCRF screen failure form.
The primary  reason for screen failure is recorded in the eCRF using the following categories:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify  reason ).
Significant protocol  deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other (specify reason).
Subject numbers assigned to subjects who fail screening should not be reused.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 43of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.1.16 Documentation of Randomization
Only subjects who meet all of the inclusio n criteria and none of the exclusio n criteria are eligible 
for randomizat ion into the study . Any subjects that replace withdrawn or di scont inued subjects 
will maintain the same treatm entsequence as the discontinue d subject .
If the subject is found to be not eligible for randomizat ion, the invest igator should record the 
primary  reason for failure on the applicable eCRF.
9.2 Monitoring Subject Treatment Compliance
Study  medicat ion will be administered while subjects are under observation in the clinical research 
unit. Following administration of the study medicatio n, appropriate mouth and/or hand checks will 
be performed to ensure that the dose is swallo wed and noted in the source document. The date and 
time of each dose will be recorded to the nearest minute on the source document and the eCRFs. 
The exact dose time of consecutive subjects may be staggered to facilitate logistics at the site.
9.3 Schedule of Observations and Procedures
The schedule for all study -related proced ures for all evaluat ions is shown in Appendix A. 
Assessments should be co mpleted at the designated visit/time po ints.
9.3.1 Screening 
Subjects will be screen ed wi thin 28 days prior to randomizat ion. Subjects will be screened in 
accordance with predefined inclusio n and exclusio n criteria as described in Sect ion
 7.0. See 
Secti on
 9.1.1 5for procedures for documenting screening failures.
Procedures to be completed at Screening include:
Inform ed consent.
Dem ographics, m edical history , and medicat ion history .
Physical examinat ion.
Vital signs.
Weight, height, and BMI.
Concomitant medicat ions.
Concurrent medical condit ions.
Fasting Screening clinical laboratory tests (hematology, serum chemistry , urine analysis, 
hepat itis panel, urine drug screen).
12-lead ECG procedure.
Assessment of inclusio n/exclusion criteria.
Pregnancy test (women of childbearing potential).
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 44of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALFSH (only  performed if menopause is suspected).
Pretreatment event assessment.
9.3.2 Check -in (Day -1)
Subjects will b e admi tted to the clinic on Check -in (Day  -1). The fo llowing procedures will be 
perform ed; all  resul ts must be available prior to administration of study  drug on Day  1:
Confinement.
Assessment of inclusio n/exclusion criteria (Period 1 only).
Com plete physical examinat ion.
12-lead ECG.
Vital signs.
Fasting laboratory  evaluat ions (after a minimum 8 -hour fast).
Serum  pregnancy test (females of childbearing potent ial only).
Urine drug screen, alcoho l screen, and cotinine screen.
AEs: Pretreatment events ar e assessed on Day  -1 of Period 1 and TEAEs are assessed on Day  
-1 of Period 2. 
Concomitant medicat ion assessment.
9.3.3 Treatment Phase (Day 1)
The fo llowing procedures will be performed at Day 1:
Randomization (Period 1 only).
Confinement.
Vital signs (blood p ressure and pulse only) prior to dose and 8 hours postdose.
Concomitant medicat ion assessment.
Administrati on of  study  drug.
PK blood sampling.
Pharmacogeno mic sample co llection (Period 1 only).
Pretreatment event/AE assessment.
For Peri od 1, if the subjec t has sat isfied all o f the inclusion criteria and met none of the exclusio n 
criteria for randomizat ion, the subject should be rando mized as described in Sect ion 8.3. The 
procedure for document ing screening failures is provided in Sect ion
 9.1.15 .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 45of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.3.4 Day 2 (Period 1) 
The fo llowing procedures will be performed at Day 2 (Period 1):
Confinement.
PK blood sampling.
AE assessment.
Concomitant medicat ion assessment.
12-lead ECG.
Vital signs (blood pressure and pulse only).
Fasting laboratory  evaluat ions (after a minimum 8 -hour fast).
9.3.5 Day 2 (Period 2)/Study Exit 
The Final Visit will be performed on Day  2 of Period 2 or at the Early  Terminat ion Visit. The 
following procedures will be performed and documented on Day  2 of Period 2:
Confinement.
Com plete physical  examinat ion (excluding genitourinary  examinat ion).
12-Lead ECG.
Vital signs (bl ood pressure and pulse only).
Fasting laboratory  evaluat ions (after a minimum 8 -hour fast).
Serum  pregnancy test (females of childbearing potent ial only).
PK blood sampling.
AE assessment.
Concomitant medicat ion assessment.
For all subjects receiving study drug, the invest igator must complete the End -of-Study  eCRF page.
9.3.6 Early Termination
Com plete physical  exam (excluding genitourinary examinat ion).
12-Lead ECG.
Vital signs.
Fasting laboratory  evaluat ions. (If an 8 -hour fast i s not possible at Early terminat ion, 
laboratory  samples will st ill be co llected .)
Serum  pregnancy test (females of childbearing potent ial only).
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 46of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALPretreatment event/AE assessment.
Concomitant medicat ion assessment.
9.3.7 Follow -up 
At 10±2 days fo llowing the last dose of study drug, a fo llow-up phone call will be made to inquire 
about any  ongoing or new AEs, any  SAEs, and concomitant medicat ions taken since final dose. 
Any spontaneously  reported AEs will cont inue to be co llected for 30 days after the last dose of 
study  drug. Subj ects who wi thdraw thei r consent shoul d still be contacted for a safety  follow-up 
call. The contact should only be recorded in their source documents and the eCRFs, according to 
data protecti on regul ations.
9.3.8 Unscheduled Visit
1.Com plete physical  examinat ion.
2.Vital signs.
3.AE a ssessment.
4.Concomitant medicat ion assessment.
9.4 Biological Sample Retention and Destruction
In this study, specimens for genome/gene analysis will be collected as described in Section 9.1.12 . 
The genetic material will be preserved and retained at Covance Biorepository  for up to, but not 
longer than, 15 y ears, or as required by applicable law. The sponsor has put into place a syst em to 
protect the subjects’ personal informat ion to ensure optimal confident iality and defined standard 
processes for sample and data collect ion, storage, analysis, and destruction.
The samples will be sent to a central laboratory  that processes the blood sample and serves as a 
secure storage facilit y. The sponsor and researchers working with the sponsor will have access to 
the sam ples collected and any  test resul ts. All  sampl es collected during the study  will be stored 
securely  with limited access and the sponsor will require any one who works wi th the sam ples to 
agree to hold the research informat ion and any results in confidence.
The sample will be labeled with a unique sample ident ifier similar to labeling in the main study but 
using a code that is differ ent from the code attached to the health information and other clinical test 
resul ts collected in the study . The sample and data are linked to personal health informat ion with 
code numbers; the samples are stripped of all personal identifying information b ut a key  linking 
the sam ples to clinical analysis data exists. This link means that the subject may  be identified but 
only indirect ly. The code numbers will be kept secure by, or on behalf o f, the sponsor.
Subjects who consented and provided a PGx sample f or DNA analysis can wit hdraw their consent 
and request disposal o f a stored sample at any  time pri or to analysis. Notify sponsor of consent 
withdrawal .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 47of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL9.5 Blood Volume
Total  blood sam pling vo lume for an individual subject is shown in Table 9.c.
Table 9.c Approximate Blood Volume
Approximate Blood Volume
Sample TypeSample 
Volume 
(mL)Number of SamplesTotal Volume 
(mL)
Screening Period 1 Period 2
Clinical Laboratory 
Test Samples20 1 2 2 100
PK Samples 4 0 15 15 120
PGx DNA 6 0 1 - 6
Total Blood Sampling Volume 226
The m aximum  volume of  blood at any  single day  is approximately  96 mL, and the approximate 
total volume of blood for the study  is 226 m L.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 48of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS
10.1 Definitions
10.1.1 Pretreatment Events 
A PTE i s defined as any  untoward m edical  occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a stu dy but pri or to administration of any study  
medicat ion; it does not necessarily have to have a causal relat ionship with study  parti cipat ion.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject 
administered a drug; it does not necessarily have to have a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug whether or 
not it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Intermittent 
events for pre -exist ingcondi tions underlying disease should not be considered PTEs or AEs).
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason. 
PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:
Each event should be recorded to represent a single  diagnos is. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory values or ECG parameters are only considered to be PTEs or AEs if the y 
are judged to be clinically significant (ie, if some action or intervent ion is required or if the 
investigator judges the change to be bey ondthe range of normal physio logic fluctuati on). A 
laboratory  re-test and/or continued monitoring o f an abnormal value are not considered an 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 49of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALintervent ion. In addit ion, repeated or addit ional noninvasive testing for verificat ion, evaluatio n 
or monitoring of a n abnormalit y is not considered an intervent ion.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriat ely as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, ECG, X -rays, etc.) should NOT be recorded as PTEs unless 
related to study  procedures. However, if the subject experiences a worsening or complication 
of such a concurrent condit ion, the worsening or complicat ion shoul d be recorded 
appropriately  as a PT E (worsening or complicat ion occurs before start of study medicat ion) or 
an AE (worsening or complicat ion occurs after start of study medicat ion). Investigators should 
ensure that the event term recorded captures the change in the condit ion (eg, “worsening
of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy) any occurrence of an 
episode should only be captured as a PTE/AE if the episodes beco me mo re frequent, serious or 
severe in nature, that is, invest igators should ensure that the AE term  recorded captures the 
change in the condit ion from Baseline (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion shoul d only  be captured as a PTE/AE if occu rring to a greater 
extent to that which would be expected. Again, investigators should ensure that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Worsening of PTEs or AEs:
If the subject experiences a worsening or complica tion of a PTE after starting administration of 
the study  medicat ion, the worsening or complicat ion should be recorded appropriately as an 
AE. Invest igators should ensure that the AE term recorded captures the change in the condit ion 
(eg, “worsening of…”).
If the subject experiences a worsening or complication of an AE after any  change in study  
medicat ion, the worsening or complicat ion should be recorded as a new AE. Investigators 
shoul d ensure that the AE term recorded captures the change in the condit ion (eg, “worsening 
of…”).
Changes in severit y of AEs /Seri ous PTEs:
If the subject experiences changes in severit y of an AE/seri ous PTE, the event should be 
captured once with the maximum severit y recorded.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 50of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALPrepl anned surgeries or procedures:
Prepl anned proced ures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
perform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
worseni ng of the condit ion should be captured appropriately as a PTE or an AE. Complicat ions 
resul ting fro m any planned surgery  shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as PTEs or AEs, but should be documented in the subject’s source 
docum ents. Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
Cases of overdose with any  medicati on wi thout m anifes ted si de effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.4 SAEs
An SAE is defined as any untow ard m edical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisf ies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 51of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALTable 10.a Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndromeHepatic necrosis
Torsade de pointes/ventricular fibrillation/ventricular 
tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary fibrosis
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens -Johnson syndrome Confirmed or suspected transmission of infectious agent by 
a medicinal product
Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and fo llowed up in the same manner (see Sections 10.2.2 and 10.3) .
10.1.5 Severity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The e vent is transient and easily tolerated by the subject.
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
10.1.6 Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for whi ch possible involvement of the drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reas onable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments.
10.1.7 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relations hip should be assessed 
as Not Related.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 52of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL10.1.8 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by  the subject 
and/or physician.
10.1.9 Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the even t resolved but with 
sequelae or the subject died.
10.1.10 Frequency 
Episodi c AEs/PTE (eg, vomit ing) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.11 Action Concerning Study Medication 
Drug withd rawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  medicat ion.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not Applicable –a study  medicati on was stopped for a reason other than the particular AE, 
eg,the study  has been terminated, the subject died, dosing with study  medicat ion was already 
stopped before the onset of the AE.
Dose reduced –the dose was reduced due to the part icular AE.
Dose interrupted –the dose was interrupted due to the particular AE.
10.1.12 Outcome
Recovered/Resolved –subject returned to first assessment status with respect to the AE/PTE.
Recovering/Reso lving –the intensit y is lowered by  one or m ore stages: the diagnosis or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/r esolving”.
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study  period has gotten worse than when it started; is an irr eversible congenital ano maly; the 
subject died fro m another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.
Reso lved with sequelae –the subject recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairmen t (eg, recovered from a cardiovascular accident but with 
some persisting paresis.
Fatal  –the AEs/PTEs which are considered as the cause of death.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 53of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALUnknown –the course of the AE/PTE cannot be followed up due to hospital change or 
residence change at the en d of the subject’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTEs and AEs Collection Period
Collect ion of PTEs will co mmence from the time the subject signs the informed consent to 
participate in the study  and cont inue until the subject i s first administered study  medicat ion 
(Day 1) or until screen failure. For subjects who discontinue prior to study  medicat ion 
administration, PTEs are collected unt il the subject discont inues study participation.
Collect ion of AEs will co mmenc e from the time that the subject is first administered study  
medicat ion (Day 1). Routine collection of AEs will continue until 5 to 10 days after the last dose of 
study  drug is completed. Any spontaneously reported AEs will cont inue to be reported for 30 d ays 
after the l ast dose of study  drug.
10.2.1.2 PTEs and AEs Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects may report AEs occurri ng at any  other time during the study . Subjects experi encing a 
serious PTE m ust be monitored until the symptoms subside and any clinically relevant changes in 
laboratory  values have returned to Baseline or there is a sat isfactory  expl anati on for the change. 
Nonserious PTEs, related or unrelated to the study  procedure, need not be fo llowed-up for the 
purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust b e monitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the e CRF, 
whether or not the invest igator concludes that the event is related to the drug treatment. The 
following informat ion will be documented for each event:
1.Event term .
2.Start and stop date and time.
3.Frequency.
4.Severit y.
5.Invest igator’s opinio n of the causal relationship between the event and administration of study 
medicat ion(s) (rel ated or not rel ated) (not completed for PTEs).
6.Invest igator’s opinio n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 54of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL7.Action concerning study  medicat ion (not applicable for PTEs).
8.Outcom e of event.
9.Seriousness .
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period, it should be reported according to the 
following procedure:
A Takeda SAE form must be completed in English and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the re ason the event is categorized as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 1.0. 
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to st udy participat ion.
Reporting of serious PTEs will fo llow the procedure described for SAEs.
10.2.3 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3 ×ULN on 2 consecut ive occasions, the 
abnorm ality shoul d be recorded as an AE. In addition, an LFT Increases eCRF must be co mpleted 
provi ding addit ional information on relevant recent history , risk factors, clinical signs and 
symptoms and results of any addit ional diagnosti c tests performed.
If a subject is noted to have ALT or AST >3 × ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on
 10.2.2 . The investigator must con tact the Medical Monitor for discussio n of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease or medical history /concurrent m edical  condi tions. Fo llow-up laboratory  
tests as described in Sect ion
 9.1.8 must also be performed. In addit ion, an LFT Increases eCRF 
must be completed and transmitted wi th the Takeda SAE form (as per Section 10.2.2 ). 
10.3 Follow -up of SAEs
If informat ion that i s not available at the time of the first report becomes available at a late r date, 
the invest igator should co mplete a fo llow
-up SAE form  or provide other wri tten documentati on 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 55of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALand fax i t immediately wit hin 24 hours of receipt. Copies of any relevant data fro m the hospi tal 
notes (eg, ECGs, laboratory  tests, di scharge summary , post mortem resul ts) shoul d be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.1 Safety Reporti ng to Investigators, IRBs and Regulatory Authorities 
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators, and IRBs, as 
applicable, in accordance with national regulat ions in the countries where the study  is conducted. 
Relative to the first awareness o f the event by /or further provisio n to the sponsor or sponsor’s 
designee, SUSARs will be submitted to the regulatory  authori ties as an expedi ted report wi thin 7 
days for fatal and life -threatening events and 15 days for other serious events, unless otherwise 
requi red by nat ional regulations. The sponsor will also prepare an expedited report for other safet y 
issues where these might materi ally alter the current benefit -risk assessment of an invest igational 
medicinal product or that would be sufficient to consider changes in the invest igational medicinal 
products administration or in the overall conduct of the study . The invest igational sitealso will 
forward a copy  of all expedited reports to his or her IRB or IEC in accordance wit h nat ional 
regul ations.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 56of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL11.0 STUDY- SPECIFIC COMMITTEES
No steering committee, data safety  monitoring commi ttee, or clinical endpoint committee will be 
used in this stud y.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 57of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL12.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history, and concurrent condit ions will be coded using the Medical Dict ionary 
for Regul atory  Activit ies (MedDRA). Drugs will be coded using the World Health Organizat ion 
Drug Dict ionary (WHODRUG).
12.1 CRFs (Electronic)
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with acce ss to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be com pleted in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti onsto eCRFs are recorded in an audit trail that captures the old information, the new 
inform ation, identificat ion of the person making the correction, the date the correction was made, 
and th e reason for change. Reasons for significant corrections should addit ionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigat or must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator wi th use of change and modificat ion records of 
the eCRFs. The principal investigator must review the data change for completeness and accuracy, 
and must sign and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic vis its 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stip ulated in Secti on 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the in formed consent forms), 
and detailed records of drug disposit ion to enable evaluat ions or audits fro m regulatory  authorit ies, 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 58of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALthe sponsor or its designees. Any source documentation printed on degradable thermal sensit ive 
paper should be photocopied by  the s ite and filed with the original in the subject’s chart to ensure 
long-term legibilit y. Furthermore, International Conference on Harmonisat ion (ICH) E6 
Secti on4.9.5 requi res the investigator to retain essent ial docum ents specified in ICH E6 
(Secti on8) unt il at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorities are n otified. In addit ion, ICH E6 
Secti on 4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the invest igator and sp onsor.
Refer to the Phase 1 Site Specificat ions docum ent for the sponsor’s requirements on record 
retenti on. The invest igator should contact and receive written approval fro m the sponsor before 
disposing of any such documents.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 59of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL13.0 STATISTICAL METHODS
13.1 Statistic al and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to database lock. This 
docum ent will provi de further details regarding the definit ion of analysis variables and analysis 
methodol ogy to address all study  objecti ves.
A targeted data review will be conducted prior to database lock. This review will assess the 
accuracy  and completeness of the study  database, subject evaluabilit y, and appropri ateness of the 
planned statistical methods.
13.1.1 Analysis Sets
Safety Set: All subjects who enroll into the study  and take at l east 1 dose of study  drug will be 
included in the safet y set.
PK Set: All subjects in the safet y set who have at least 1 valid plasma concentration of 
dexlansoprazole at scheduled sample collection t ime will be included in the PK set.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
For each part, demographic and baseline characteristics will be summarized by sequence and 
overall. Summary statist ics (number of subjects, mean, median, standard deviat ion and range) will 
be generated for continuous variables (eg, age, weight, and BMI) and the number and percentage 
of subjects wi thin each category  will be presented for categorical variables (eg, gender, race, and 
ethnicit y).
13.1.3 PK Analysis
For each regimen of each part, dexlansoprazole plasma concentrations and PK parameter estimates 
will be tabulated and descriptive statist ics co mputed.
For each part, analysis o f variance (ANOVA) will be performed on natural logarithms of 
dexlansoprazole C maxandAUC with factors for sequence, the subject nested within sequence, 
period and regimen. The factor of the subject nested within sequence will be the error term for 
testing the sequence effect. Other factors will be tested with the residual as the error term . For the 
relative BA determinat ion, pai rwise com parisons will be performed to assess the relat ive BA of 
dexlansoprazole via po int estimates and 90% confidence interval (CI) for the ratio of C maxand 
AUC central values of the dexlansoprazole 30 mg or 60 mg capsules manufactured at TOB 
compared wi th the respect ive dexlansoprazole 30 mg or 60 mg capsules manufactured at TPC. A 
concl usion of BE i n the PK o f dexlansoprazole between test regimen (dexlansoprazole capsule -
TOB) and the reference regimen (dexlansoprazole ca psule -TPC) will be reached if the 90% CIs 
for C maxand AUC are within the (0.80 -1.25) interval . 
Statistical analyses of other plasma PK parameters will be performed if appropriate.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 60of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL13.1.4 Safety Analysis
AEs will be summarized using the safet y analysis set. AE s that started or worsened in severit y 
after the first dose of study drug will be summarized by regimen. AEs will be classified according 
to MedDRA system organ class, high -level term and preferred term. Summary tables for AEs will 
include numbers and perc entages of subjects experiencing AEs by system organ class and 
preferred term. The following summary tables will be included in the report by intervals: summar y 
of AEs, drug -related AEs, relat ionship o f AEs to study drug, severit y of AEs and related AEs. A Es 
leading to study  drug di scontinuat ion and SAEs will be listed.
Baseline, postdose, and change fro m Baseline to postdose laboratory , vital sign values will be 
summarized by  regimen utilizing descript ive statistics. Criteria for markedly abnormal laborato ry 
and vital sign values (markedly  abnorm al values [MAVs]) will be presented and the number and 
percentage of subjects with at least 1 markedly abnormal laboratory  test resul t will also be 
summarized by  regimen.
Shift tables for character ECG results will be provided overall to tabulate the number and 
percentage of subjects who changed status after dosing. 
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3 Determination of Sample Size
For each part, a sample size of 52 (26 per sequence) will be used in this study. This sample size will 
allow for up to 6 dropouts (11.5% dropout rate) and provide 90% probabilit y of concluding 
equivalence on dexlansoprazole C maxbetween the 2 regimens if the true difference between 
dexlansopraz ole C maxcentral  values from 2 regimens is no more than 5%. The power for 
concl uding equivalence on dexlansoprazole AUC between 2 regimens would be over 90%. This 
sample size was based on the intrasubject variance of 0.075 for log(C max) and 0.024 for log(A UC) 
from the TAK -390MR_107 study .
If BE is not achieved with the first TOB formulat ion assessed, the study  may be repeated in new 
subjects who will receive the same TOB formulat ion or a different TOB formulation. The same 
study  design will  be utilized if addi tional formulation assessments are needed.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 61of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (contract research organizat ion [CRO]) and by the IRB or independent ethics committee 
(IEC).
All aspects of the study and its documentation will be subject to review by the sponsor or designee, 
including but not limited to the Invest igator’s Binder, study  medicat ion, subject medical records, 
inform ed consent docum entati on, docum entati on of subject authorizat ion to use personal healt h 
inform ation (if separate fro m the inform ed consent form s), and review o f eCRFs and associated 
source documents. It is important that t he invest igator and other study personnel are available 
during the monitoring visits and that sufficient time is devoted to the process.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immed iate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropria te course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the site shoul d notify  the sponsor or i ts desi gnee (and IRB or IEC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary st udy 
assessment. A Protocol Deviation Form should be completed by the site and signed by the sponsor 
or desi gnee for any  significant deviat ion from the protocol.
Every  attem pt will be m ade to collect each PK blood sample at the designated time point, and th e 
actual t ime of each blood sample will be recorded on the source document and eCRF. However, 
blood sam ples not collected as displayed in Table 14.ashoul d be reporte d to Takeda using the 
Protocol  Deviat ion Form . 
Table 14.a Windows for PK Sample Collection
Minutes Nominal Sampling Time
No more than 30 minutes predose 0 hour
±5 Immediately postdose to ≤6 hours
±10 >6 hours to ≤12 hours postdose
±15 >12 hours to ≤24 hours
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 62of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALShoul d other unexpected circumstances arise that will require deviation from protocol -specified 
procedures, the invest igator should consult with the sponsor or designee (and IRB as required) to 
determine the appropriate course of action. There will be no exemptions (a prospective approved 
deviat ion) from the inclusio n or exclusio n criteria.
The sponsor or designee contact informat ion for communicat ing protocol deviat ions is provided in 
Secti on 1.1. 
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency  [MHRA], the Pharmaceuticals and Medical 
Devices Agency 
[PMDA] of Japan). If the study site is contacted for an inspect ion by a regulatory body, the sponsor 
shoul d be notified immediately. The invest igator and inst itution guarantee access for qualit y 
assurance auditors to all study  docum ents as d escribed in Sect ion 14.1.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 63of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, su bjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulat ory requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki a re addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilit
ies.
15.1 IRB Approval
IRBs m ust be consti tuted according to the applicable state and federal requirements of each 
participat ing region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB. If any member of the IRB has direct 
participat ion in this study , written notificat ion regarding his or her abst inence fro m voting must 
also be obtained. Those Americas sites unwilling to provide names and tit les of all members due to 
privacy  and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or comparable number assigned by the Department of Health and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, package 
insert, a copy of the informed consent form, and, if applicable, subject recruit ment materials and/or 
advert isements and other documents required by all applicable laws and regulat ions, m ust be 
submitted to a central or local IRB for approval. The IRB’s written approval of the protocol and 
subject inform ed consent m ust be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specific 
screening activit y). The IRB approval must refer to the study  by exact protocol  title, number, and 
versio n date; ident ify versio ns of other documents (eg, informed consent form) reviewed; and state 
the approval date. The sponsor will notify the site of drug shipment once the sponsor has 
confirmed the adequacy of site regulatory  docum entati on and, when applicable, the sponsor has 
received permissio n from competent authori ty to begin the study . Until the si te receives 
notification to proceed with the study , no protocol  activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by their respect ive IRB. This may include 
notification to the IRB regarding protocol amendments, updates to the informed consent form, 
recrui tment m aterials intended for viewing by  subjects, l ocal safet y reporti ng requirements,
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB, and submissio n of the investigator’s final status report to the IRB. All IRB 
approval s and rel evant docum entati on for these i tems must be provi ded to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB and sponsor.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 64of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable ), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject i nform ation sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fac t that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if app licable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, s ubject authori zation form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the inf ormed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by  the IRB or IEC .
The subject must be given ample opportunit y to: (1) inquire about details of the study  and 
(2)decide whether or not to participate in the study. If the subject determines he or she will 
participate in the study , then the informed consent form and subjec t authori zation form (if 
applicable) must be signed and dated by the subject at the time of consent and prior to the subject 
entering into the study . The subject shoul d be instructed to sign using their legal names, not 
nicknames, using blue or black ballp oint ink. The investigator must also sign and date the informed 
consent form and subject authorizat ion (if applicable) at the time of consent and prior to the subject  
entering into the study; however, the sponsor may  allow a designee of the invest igator to sign to 
the extent permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator mus t docum ent the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and the subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by the relevant subjects in the 
same m anner as the ori ginal  informed consent. The date the revised consent was obtained should 
be recorded in the subject’s medical record, and t he subject should receive a copy of the revised 
inform ed consent form .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 65of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALSubjects who consented and provided a PGx sample for DNA analysis can wit hdraw their consent 
and request disposal o f a stored sample at any  time pri or to analysis. Notify sponsor of con sent 
withdrawal .
15.3 Subject Confidentiality
The sponsor and designees affirm and uphol d the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinica l study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, MHRA, PMDA), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent proces s (see Section 15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion removed (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriatel y reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Cl inical  Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 66of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions, and guid ance, Takeda will, at a minimum register 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along with invest igator’s cit y, state, country , and recrui ting status will be 
registered and available for public viewing. For some registries, Takeda will assist callers in 
locating trial sites closest to their ho mes by providing the investigator name, add ress, and phone 
number to the callers requesting trial informat ion. Once subjects receive invest igator contact 
inform ation, they  may call the si te request ing enro llment into the trial. The invest igative sites are 
encouraged to handle the trial inquiries ac cording to their established subject screening process. If 
the caller asks addit ional questions beyo nd the topic of trial enro llment, they should be referred to 
the sponsor. Any invest igator who objects to Takeda providing this information to callers must 
provi de Takeda with a written notice requesting that their informat ion not be listed on the registry 
site.
15.4.3 Clinical Trial Results Disclosure 
Takeda will post the results of clinical trial son ClinicalTrials.gov or other publicly  accessible 
websites, as re quired by Takeda Policy/Standard, applicable laws and/or regulat ions.
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local u nderwri ter is requi red, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clinical Study  Site Agreement regarding the sponsor’s policy on subject 
compensat ion and treatm ent for injury. If the investigator has questions regarding this po licy, he or 
she should contact the sponsor or sponsor’s designee.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 67of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL16.0 REFERENCES
1.Dexilant (dexlansoprazole) Delayed Release Capsules. Full Prescribing Informat ion. 
Deerfield, IL: Takeda Pharmaceut icals America, Inc., Revised October 2016.
2.Guidance for Industry : Bioavailabili ty and Bioequivalance Studi es Submitted in NDAs or 
INDs -General Considerations. US Dept of Health and Human Services, Food and Drug 
Administ ration, Center for Drug Evaluat ion and Research (CDER). March 2014.
3.Guideline on the Invest igation of Bioequivalence. European Medicines Agency, Committee 
for Medicinal Products for Human Use. 20 January  2010. Publicat ion No. 
CPMP/EWP/QWP/1401/98 Rev. 1 .
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 68of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAppendix ASchedule of Study Procedures
Study Day:Pretreatment 
Period Treatment Periods 1 and 2 (a)Study Exit 
(Day 2 of 
Period 2)/ 
Early 
Termination 
VisitFollow -up 
Phone Call 
(d)Days 
-28 to -2 
(screening) (b)Day -1 
(Check -in) Day 1 (c) Day 2
Confinement X X X (e) X (f)
Informed consent X
Inclusion/exclusion 
criteriaX X (g)
Demographics and 
medical historyX
Medication history X
Physical examination X X X
Height, Weight, and 
BMI (h)X
Vital signs (i) X X X X X
Concomitant 
medicationsX X X X X X
Concurrent medical 
conditionsX
Clinical laboratory 
tests (j)X X X X
Hepatitis panel X
Pregnancy test (hCG) 
(k)X X X
FSH (l) X
Urine drug screen X X
ECG (m) X X X X
Administration of 
study  drug (n) X
PGx DNA sample 
collection (o)X
PK blood collection 
(p)X X X (q)
AE assessment (r) X X X X X X
Footnotes are on last table page.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 69of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL(a) There will be at least 5 days between the dose in 1 period and the dose in a subsequent period.
(b) Screening procedures must be performed within 28 days prior to administration of investigational product.
(c) Day 1 of each treatment period.
(d) Follow -up phone call will be made 10±2 days after last dose of study drug to inquire about any TEAE or SAEs, and concomitant 
medications taken since final dose. Any TEAE/SAE spontaneously reported within 30 days postdose will be included within the 
database as a TEAE.
(e) Following study procedure completio n on Day 2 of Period 1, subjects will be discharged from the clinic to begin the washout 
period. 
(f) Following study procedure completion on Day 2 of Period 2, subjects will be discharged from the clinic. Early termination
procedures are explained in Sect ion 9.3.6 .
(g) Assessment of inclusion and exclusion criteria will be done on Day -1, Period 1 only. 
(h)The BMI is calculated using metric units as follows: Metric: BMI = weight (kg)/[height (m)]2.
(i) Vital signs: oral body temperature, sitting blood pressure (after resting 5 minutes), respiratory rate, and pulse (beats per minute) 
at Screening. Only blood pressure and pulse will be collected on Check -in (Day - 1) through Day 2 of each period prior to dose and 
8hours postdose, or if the subject terminated early from study. When vital signs are scheduled at the same time as blood draws , the 
blood draw will take priority and vital signs will be obtained within 3 0 minutes before or after the scheduled blood draw .
(j) Hematology, serum chemistries, and urinalysis tests. Clinical laboratory samples will be collected after a minimum of an 8 hour 
fast on Screening, Check -in (Day -1) of Periods 1 and 2; Day 2 of Period 1, and Study Exit (Day 2 of Period 2)/Early termination. If 
an 8-hour fast is not possible at Early termination, laboratory samples will still be collected.
(k) A serum pregnancy test will be done at Screening and Day -1 of each period, Study Exit (Day 2 of Period 2), or if a subject 
prematurely terminates from the study.
(l) For women where menopause is suspected (see Section 9.1.9 ).
(m) ECG performed at Screening, Check -in (Day -1 of Period 1), and Study Day 2 of each period, or if a subject terminates early 
from the study. 
(n) Study drug will be administered on Day 1 of each period at approximately 0800 hours, following a 10- hour fast. Dosing may be 
staggered to help facilitate logistics at the site.
(o) One 6 mL whole -blood sample will be collected for DNA analysis prior to dosing on Day 1 of Period 1 only. 
(p) Blood samples for PK obtained predose (within 15 minutes prior to dose), and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, and 
24hours post Day 1 dosing in each period. 
(q) The PK sample should not be collected at the Early Termination Visit if a PK collection is not scheduled.
(r) Pretreatment AEs will be captured immediately following the signing of the informed consent at Screening until dosing on 
Day1 of Period 1. The routine collection of AEs will continue after dosing through the follow -up phone call.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 70of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical researc h studi es sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study . 
The invest igator agrees to assume the fo llowing responsibilit ies:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protoc ol.
3.Ensure that study -related procedures including study -specific (non routine/non standard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authorit ies.
4.Ensure th at all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval of the study  and any  changes by  an appropri ate IRB that conform to 
ICH, and l ocal regul atory  requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the stud y to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
7. Ensure that requirements for informed consent, as outlined in ICH and local regulations, are 
met.
8.Obtain valid informed consent from each subject who participates in the study ,and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject autho rization form from each subject.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow poss ible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 71of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 72of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAppendix CElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provi ded to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The identificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the pr obabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o,fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appr opriate al ternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will b e maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subject is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights , IRB/IEC, and whom to contact in the event of a 
research -related inj ury to the subject.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and th at the subject may discont inue 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 73of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALparticipat ion at any  time wi thout penal ty or loss of benefits to which the subject is otherwise 
entitled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of participation by the subject.
21.A statement that the subject will be informed in a timely manner if informat ion beco mes 
available that may be relevant to the subject’s willingness to continue participat ion in the 
study .
22.A statement that results of PGx analys is will not be disclo sed to an individual, unless 
prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contain ed within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ingthe study . The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to ot her parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offe r 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients , 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 74of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL25.Women of childbear ing potential (eg, nonsterilized, premenopausal wo men) who are sexually 
active must use adequate contraception (as defined in the informed consent) from Screening 
and throughout the duration of the study , and for 30 day s after l ast dose of study  medicat ion. 
Regular pregnancy tests will be performed throughout the study for all women of childbearing 
potenti al. If a subject is found to be pregnant during study , study  medicat ion will be 
discontinued. 
26.Men must use adequate contraception (as defined in the info rmed consent) fro m Screening and 
throughout the duration of the study. If the partner or wife of the subject is found to be pregnant 
during the study , or f or 30 day s after the l ast dose, the pregnancy  will be recorded following 
authori zation from the subje ct’s partner.
27.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as clinicaltrials.gov. 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 75of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAppendix DInvestigator Consent to Use of Personal Informatio n
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countr ies throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details, and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purpos es described above.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 76of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAppendix ECollection, Storage, and Shipment of Bioanalyt ical Samples 
1. Collect 4 mL of venous blood into a chilled Becton- Dickinson Vacutainer. All 
dexlansoprazole blood samples should be co llected into Va cutainers containing K2EDTA.
2.Gent ly invert the Vacutainer several t imes to mix the addit ive with the collected blood prior to 
centrifugation and place immediately on ice.
3.Centrifuge the Vacutainers for 10 minutes at a relative centrifugal force of approxim ately  1100 
to 1300 in a refrigerated centrifuge. Note: if using a collect ion device other than the 
Becton -Dickinso n Vacutainer, refer to manufacturer’s instruction for proper centrifugat ion 
force and t ime.
4.Immediately fo llowing centrifugat ion, gent ly remov e plasma fro m the packed cells. To ensure 
a more hom ogeneous sample, all plasma should first be transferred into 1 aliquot. From there, 
split the plasma evenly between the 2 aliquots. A minimum o f 0.6 mL needs to be obtained for 
each sample. Labeling may i nclude protocol  number [TAK -390MR -1001], sam ple matrix (i e, 
plasma), randomizat ion number, period, nominal day and time, analyte (dexlansoprazole), and 
either “SET 1” (for ori ginal  sample) or “SET 2” (for duplicate sample).
5.Cap the labeled storage tubes an d freeze the pl asma sam ples immediately at approximately  
-20°C or lower until shipment to PPD Development, Middleton, WI. No more than 45 minutes 
will elapse between blood collect ion and freezing the plasma sample.
Shipping of Plasma Samples
The fo llowing instructions are recommended unless they  differ from  the si te’s standard operating 
procedures (SOPs) for labeling, packaging, or shipping of PK samples.
1.Biological samples shoul d be shipped on sufficient dry  ice to prevent thawing during transit. 
Samples s hould be shipped to arrive at the destinatio n during normal business hours (local 
time). For US domest ic shipments, it is reco mmended that samples be shipped on Monday, 
Tuesday or Wednesday and 2 day s before a nat ional holiday , in order to minimize the 
possibilit y of samples arriving at their destination on a weekend or holiday. For shipments 
outsi de these peri ods, and for international shipments, it is recommended that a premium 
carrier who will replenish dry  ice during shipment as necessary  be used. Other shipping 
arrangements may be allowed with the agreement of the sponsor. If duplicate samples are to be 
shipped, send SET 1 samples and await confirmat ion of arrival before shipping the duplicate 
SET 2 samples.
2.Before shipping, make sure the sample tubes a re tight ly sealed. Separate each subject’s 
samples as fo llows:
3.Separate the duplicate SET 2 samples from the SET 1 samples.
4.Place SET 1 samples for each subject into a self -sealing bag (eg, Ziploc) containing addit ional 
absorbent material.
5.Using a permanen t marker, wri te the 4 -digit randomizat ion sequence number, sample matrix 
(ie, plasma), number of samples, and “SET 1” on each self- sealing bag.
Dexlansoprazole Delayed-Release Capsules
Study No. TAK-390MR-1001 Page 77 of 82Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL6. Place the bags of individual subject’s samples into a larger plastic bag so that samples are 
double bagged. Duplicate SET 2 samples should be returned to the freezer for storage. Repeat 
steps 3 through 6 above when preparing duplicate samples for shipment, except self-sealing 
bags should be marked “SET 2.” 
7. An inventory of individual samples should accompany each shipment and should include the 
sponsor’s name (Takeda), study medication (dexlansoprazole delayed-release capsule), 
protocol number (TAK-390MR-1001), investigato r’s name, sample type (ie, plasma), 
randomization number, period, nominal day and time, and intended sample storage conditions. 
When duplicate SET 2 samples are being shipped, make a copy of the original SET 1 sample 
inventory and mark as “SET 2.” Place the inve ntory paperwork into a large self-sealing bag. 
SET 1 samples will be shipped first on dry ice, followed by shipment of duplicate SET 
2 samples after SET 1 samples have been received by the analytical laboratory.
8. For sample packing, utilize dry ice generously (eg, 20 to 25 pounds per day of transit) to 
safeguard against longer-than-expected shipping times and delays. Use newspaper or other 
material to insulate the double-bagged samples from direct contact with the dry ice. Place the 
sample bundles into a polystyrene plastic (eg, Styrofoam) container (or other suitable 
container) and fill the excess space with dry ice slabs or ice pellets (preferably the latter). Make 
a note of the estimated weight of the dry ice used per shipping container.
9. Place the inventory paperwork (in a large self-sealing bag) on top of the dry ice in the 
polystyrene plastic container. Place the lid on the polystyrene plastic container and seal 
completely with strapping tape. Place the polystyrene plastic container in a cardboard shipping 
carton and seal securely with strapping tape.
10. Mark the outside of shipping carton(s) with a tally number (eg, 1 of 5, 2 of 5).
11. Affix an address label to each shipping carton. Complete the address label with the following 
information:
Plasma Samples for dexlansoprazole delayed-release capsules:
12. Affix a carbon dioxide label on each carton, specifically:
Carbon Dioxide Solid UN-1845
Class 9 PKG GR III
Quantity _____________________ (fill in weight to nearest lb/kg and specify unit of measure 
used)Personal Protected Data
Dexlansoprazole Delayed-Release Capsules
Study No. TAK-390MR-1001 Page 78 of 82Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIAL13. Affix 2 dry ice symbol labels on opposite sides of the carton. Mark KEEP FROZEN on each 
carton. Specify a return address and contact person on the carton.
14. Obtain the airway bill number and a receipt of shipment from the carrier.
15. After shipping of the samples, please contact the following to notify them of next day delivery.
16. When calling, provide the following information:
Name of courier or transport company
Time and date the shipment left the clinical site
Airway bill numberPersonally Protected Data
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 79of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALAppendix FDetailed Description of Amendments to Text
The sect ions of the protocol  affected by the changes in Amendment No. 02 are indicated.
Change 1: Allow the replacement of subjects who are discontinued or withdrawn.
The change occurs in Sect ion 7.6Procedures for Discontinuat ion or Wi thdrawal  of a Subject .
Initial 
wording:The invest igator may dis continue a subject’s study participat ion at any t ime during the 
study  when the subject meets the study terminat ion criteria described in Sect ion 7.5. In 
addition, a subject m ay discontinue his or her participat ion without giving a reason at 
any time during the study . Shoul d a subject’s participat ion be discont inued, the 
primary  criterion for terminat ion must be recorded by  the investi gator. In addi tion, 
efforts should be made to perform all procedures scheduled for the Early Terminat ion 
Visit. Discontinued or wi thdrawn subjects will not be replaced.
Amended 
or new 
wording:The invest igator may discont inue a subject’s study participat ion at any t ime during the 
study  when the subject meets the study terminat ion criteria described in Sect ion 7.5. In 
addition, a subject m ay discontinue his or her participat ion without giving a reason at 
any time during the study . Shoul d a subject’s participat ion be discont inued, the 
primary  criterion for terminat ion must be recorded by  the investigator. In addit ion, 
efforts should be made to perform all procedures scheduled for the Early Terminat ion 
Visit. Discontinued or wi thdrawn subjects will notmay be replaced.
Rationale for Change:
This change was made because a greater number of subjects were discontinued or withdrawn fro m 
the study  than was ori ginally  expected.
Change 2: Correct the dose shown in Part 2 of the crossover study design schemat ic.
The change occurs in Figure 6.bSchemat ic of Crossover Design in Sect ion 6.1Study  Design .
Initial 
wording:[Dose l evel for Part 2 was indicated to be 30 mg.]
Amended 
or new 
wording:[Dose l evel for Part 2 i s indicated to be 60mg.]
Rationale for Change: 
This was corrected for consistency with the study  design. 
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 80of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALChange 3: Remove all reference to the subject’s legally  acceptable representative.
The primary  change occurs in Section 15.2 Subject Information, Informed Consent, and Subject 
Authori zation.
Initial 
wording:The informed consent form, subject authorizat ion form  (if applicable), and subject 
inform ation sheet (if applicable) must be written in a language fully co mprehensible to 
the prospective subject. It is the responsibilit y of the invest igator to explain the 
detailed elements of the informed consent form, subject authorization form (if 
applicable), and subject informat ion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possibl e and in the manner 
deem ed appropri ate by the IRB or IEC. In the event the subject is not capable of 
rendering adequate written informed consent, then the subject’s legally acceptable 
representative may provide such consent for the subject in accordance wi th applicable 
laws and regulations.
Amended 
or new 
wording:The informed consent form, subject authorizat ion form  (if applicable), and subject 
inform ation sheet (if applicable) must be written in a language fully co mprehensible to 
the prospective subject. It is the responsibilit y of the invest igator to explain the 
detailed elements of the informed consent form, subject authorization form (if 
applicable), and subject informat ion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and written form whenever possible and in the manner 
deem ed appropri ate by the IRB or IEC. In the event the subject is not capable of 
rendering adequate written informed consent, then the subject’s legally acceptable 
representative may provide such consent for the subject in accordance with applicable 
laws and regulations.
Rationale for Change: 
This change was requested by the IRB for consistency wit h the language in the inclusion criterion 
regarding subject informed consent.
The fo llowing sect ions also reflect this change:
Secti on 7.5Criteria for Discont inuation or Wi thdrawal  of a Subject .
Appendix BResponsibilit ies of the Invest igator .
Appendix CElements of the Subject Informed Consent.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 81of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALChange 4: Update the definit ions of women of (and not of) childbearing potential.
The change occurs in Sect ion9.1.9 Contraception and Pregnancy Avo idance Procedure .
Initial 
wording:*Wo men NOT of childbearing potential are defined as those who have been surgically 
sterilized (hysterectomy , bilateral  oophorectomy  or tubal  ligation) or who are 
postm enopausal (eg, defined as at least 1 y ear since l ast regular menses wi th an 
FSH>40 IU/L o r at least 5 years since last regular menses, confirmed before any study 
medicat ion is implemented).
Amended 
or new 
wording:* Women of childbearing potential are defined as any female who has 
experienced menarche and who are NOT permanently sterile or 
postmenopausal. Women NOT of childbearing potential are defined as those who 
have been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal 
ligation) or who are postmenopausal (eg, defined as at least 1 y ear since last regul ar 
menses wit h an FSH>40 IU/L or at least 5 y ears since last regular menses, confirmed 
before any study medication is implemented 12 consecutive months with no menses 
without an alternative medical cause ).
Rationale for Change: 
This was changed to reflect requested wordin g from the IRB during previous IRB review.
Change 5: Update the subject replacement information based on the allowance for replaced 
subjects.
The change occurs in Sect ion 9.1.16 Documentation of Rando mizat ion.
Initial 
wording:Only subjects who meet all of the inclusio n criteria and none of the exclusio n criteria 
are eligible for randomization into the study .
Amended 
or new 
wording:Only subjects who meet all of the inclusio n criteria and none of the exclusio n criteria
are eligible for randomization into the study .Any subjects that replace withdrawn 
or discontinued subjects will maintain the same treatment sequence as the 
discontinued subject.
Rationale for Change: 
The new text was added to reflect the allowance for replacement subjects.
Dexlansopra zole Delayed -Release Capsules
Study No. TAK -390MR -1001 Page 82of 82
Protocol Incorporating Amendment No. 02 06 June 2017
CONFIDENTIALChange 6: Clarify that an 8 -hour fast m ay not be possible at Early terminat ion.
The primary  change occurs in S ection 9.3.6 Early Terminat ion.
Initial 
wording:Fasting laboratory  evaluat ions. 
Amended 
or new 
wording:Fasting laboratory  evaluat ions. (If an 8 -hour fast is not possible at Early 
termination, laboratory samples will still be collected.)
Rationale for Change: 
This text clarifies that laboratory  samples shoul d still be collected even though subjects who 
discontinue may not have had the opportunit y to fast for 8 hours prior to the visit.
This change is also reflected in footnote j of Appendix ASchedule of Study  Procedures .
Change 7: Correct the sequence numbers in Table 8.bfor Part 2 of the study .
The change occurs in Table 8.bDose and Regimen .
Initial 
wording:[Sequence numbers for Part 2 wer e listed as 1 and 2.]
Amended 
or new 
wording:[Sequence numbers for Part 2 are now listed as 3 and 4 .]
Rationale for Change: 
This was corrected for consistency with the information presented in Table 6.bPart 2 Sequence s.
 䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   



GIF䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢴䢢䣶䣱䢢䣒䣪䣣䣵䣧䢢䢳䢢䣄䣫䣱䣧䣳䣷䣫䣸䣣䣮䣧䣰䣥䣧䢢䣕䣶䣷䣦䣻䢢䣱䣨䢢䣆䣧䣺䣮䣣䣰䣵䣱䣲䣴䣣䣼䣱䣮䣧 䢢䣅䣣䣲䣵䣷䣮䣧䣵䢢䣨䣴䣱䣯䢢䣖䣹䣱䢢䣏䣣䣰䣷䣨䣣䣥䣶䣷䣴䣫䣰䣩䢢䣒䣮䣣䣰䣶䣵
&OLQLFDO3KDUPDFRORJ\$SSURYDO -XQ87&
4XDOLW\&RQWURO$SSURYDO -XQ87&
&OLQLFDO6FLHQFH$SSURYDO -XQ87&Personal Protected Data